{"text": "Previous studies have shown that physician measures have a higher rate of placebo response , and are among the least efficient measures in clinical trials when compared with patient - reported outcomes .", "label": "", "metadata": {}, "score": "38.668907"}
{"text": "This substudy included 40 patients in the tocilizumab group and 22 in the placebo group ( see supplementary appendix , available online only , for baseline demographics and clinical characteristics ) .", "label": "", "metadata": {}, "score": "39.749184"}
{"text": "At study visits , physical and laboratory assessments were performed and information on any adverse events was ascertained .Results .Baseline characteristics were similar be- tween the rilonacept and placebo groups ( n ?", "label": "", "metadata": {}, "score": "39.972374"}
{"text": "Another factor that should be con- sidered when interpreting the present study results is the somewhat higher number of patients with tophi in the placebo group ( n ? 6 ) compared to the rilonacept group ( n ?", "label": "", "metadata": {}, "score": "40.350185"}
{"text": "Secondary endpoints for the trial included the Lower Extremity Manual Muscle Test , the Ashworth Score for spasticity , and Subject and Clinician Global Impressions .", "label": "", "metadata": {}, "score": "40.702477"}
{"text": "In addition , a significantly lower proportion of patients experienced 1 or more gout flares in the rilonacept group ( 14.6 % ) versus the placebo group ( 45.2 % ) .", "label": "", "metadata": {}, "score": "40.840267"}
{"text": "As in this study , moderate to high correlations ( 0.4 to 0.6 ) have been shown between patient global assessments and symptom measures in other therapeutic areas .", "label": "", "metadata": {}, "score": "41.22924"}
{"text": "As in this study , moderate to high correlations ( 0.4 to 0.6 ) have been shown between patient global assessments and symptom measures in other therapeutic areas .", "label": "", "metadata": {}, "score": "41.22924"}
{"text": "Compared to patients receiving placebo , patients receiving BUP TDS had a greater degree of global satisfaction , reported lower pain scores , and used less rescue medication .", "label": "", "metadata": {}, "score": "41.71077"}
{"text": "Groups were not stratified by history of TNF inhibitor use .Results .Patients .Patient disposition is shown in figure 1 .The ITT population included 614 patients , 409 and 205 in the tocilizumab and placebo groups , respectively .", "label": "", "metadata": {}, "score": "42.680508"}
{"text": "For all analyses , the a priori hypotheses were that patients perceiving more severe disease measured by PGI - S would have higher ( worse ) IPSS , IPSS - QoL , and BII scores and lower ( worse ) peak urine flow rate at V2 .", "label": "", "metadata": {}, "score": "42.889267"}
{"text": "For all analyses , the a priori hypotheses were that patients perceiving more severe disease measured by PGI - S would have higher ( worse ) IPSS , IPSS - QoL , and BII scores and lower ( worse ) peak urine flow rate at V2 .", "label": "", "metadata": {}, "score": "42.889267"}
{"text": "The proportion of patients who reported flares was also lower with rilona- cept compared to placebo throughout the 16-week double - blind treatment period ( 22.0 % [ 95 % confidence interval 11 - 38 % ] versus 47.6 % [ 95 % confidence interval 32 - 64 % ] ; P ? 0.021 )", "label": "", "metadata": {}, "score": "42.918015"}
{"text": "The study results for tadalafil efficacy versus placebo are reported elsewhere [ 12 - 15 ] .Therefore , we hypothesized that the PGI - S and PGI - I scores would be significantly and meaningfully associated with the IPSS , IPSS - QoL , and BII scores .", "label": "", "metadata": {}, "score": "43.71051"}
{"text": "The study results for tadalafil efficacy versus placebo are reported elsewhere [ 12 - 15 ] .Therefore , we hypothesized that the PGI - S and PGI - I scores would be significantly and meaningfully associated with the IPSS , IPSS - QoL , and BII scores .", "label": "", "metadata": {}, "score": "43.71051"}
{"text": "( % )Gout flare days per patient , mean ?SD Days with pain score ?5 per patient , mean ? 6.78 placebo , 0.51 ? 1.82 rilonacept ; worst observation carried forward 3.40 ?", "label": "", "metadata": {}, "score": "43.792534"}
{"text": "None of these was considered related Table 3 . 42 ) Rilonacept group ( n ?41)P % reduction , rilonacept vs. placebo Primary efficacy variable based on day 1 through week 12 Gout flares per patient , mean ?", "label": "", "metadata": {}, "score": "43.827156"}
{"text": "However , the mean IPSS scores for participants who responded \" normal \" ( 14.9 ) or \" mild \" ( 16.8 ) were significantly different from the mean scores for \" moderate \" and \" severe \" but not from each other .", "label": "", "metadata": {}, "score": "44.43227"}
{"text": "However , the mean IPSS scores for participants who responded \" normal \" ( 14.9 ) or \" mild \" ( 16.8 ) were significantly different from the mean scores for \" moderate \" and \" severe \" but not from each other .", "label": "", "metadata": {}, "score": "44.43227"}
{"text": "A higher percentage of rilonacept - treated patients ( 98 % ) compared with placebo - treated patients ( 79 % ) com- pleted the primary 12-week evaluation period ( P ?", "label": "", "metadata": {}, "score": "44.90331"}
{"text": "A total of 124 ( 38.0 % ) patients in the TCA group , 141 ( 38.6 % ) in the sham group , and 197 ( 62.3 % ) in the conservative therapy group had physiotherapy .", "label": "", "metadata": {}, "score": "45.45797"}
{"text": "The mean symptom scores for all participants for IPSS , IPSS - QoL , BII ( calculated using only data from Study 1 , 2 , and 3 ) at V2 were 19.8 , 4.1 and 6.3 , respectively .", "label": "", "metadata": {}, "score": "45.541897"}
{"text": "The mean symptom scores for all participants for IPSS , IPSS - QoL , BII ( calculated using only data from Study 1 , 2 , and 3 ) at V2 were 19.8 , 4.1 and 6.3 , respectively .", "label": "", "metadata": {}, "score": "45.541897"}
{"text": "Only 33 patients ( 16 in the TCA group and 17 in the sham acupuncture group ) stated that they had been un- blinded by the treating physician .", "label": "", "metadata": {}, "score": "45.572483"}
{"text": "Serious infections , gastrointestinal perforations and neoplasms .Twelve patients in the tocilizumab group and one patient in the placebo group had serious infections during double - blind treatment , representing a rate per 100 patient - years of 7.87 ( 95 % CI 4.30 to 13.2 ) and 1.20 ( 95 % CI 0.03 to 6.66 ) , respectively .", "label": "", "metadata": {}, "score": "45.58239"}
{"text": "For the primary efficacy analysis , Wilcoxon 's 2-sided rank sum test was used to compare the mean number of gout flares assessed from day 1 to week 12 between the 2 treatment groups .", "label": "", "metadata": {}, "score": "45.844696"}
{"text": "The dichotomized global patient assessment showed statistically significant differences among treatment groups ( P ? 0.001 for global comparison ) , with a higher rate of satisfaction in the TCA and sham acupuncture groups at week 26 ( 73.0 % for the TCA group , 62.5 % for the sham acupuncture group , and 47.1 % for the conservative ther- apy group ) .", "label": "", "metadata": {}, "score": "45.938744"}
{"text": "Statistical Analyses The sample size calculation assumed a success rate of 60 % for TCA ( 24 ) .The success rates for conservative treat- ment and sham acupuncture were assumed to be 40 % and 50 % , respectively .", "label": "", "metadata": {}, "score": "45.939026"}
{"text": "42 , respectively ) .The mean number of gout flares per patient through week 12 ( primary efficacy end point ) was markedly lower in the rilonacept group than in the placebo group ( 0.15 [ 6 flares ] versus 0.79 [ 33 flares ] ; P ?", "label": "", "metadata": {}, "score": "45.952137"}
{"text": "No serious infections were associated with a neutrophil count less than 1.0\u00d710 9 /l within 2 weeks of infection .Thirty ( 7.4 % ) patients experienced CTC grade 1 platelet levels ( 75.0\u00d710 3 /\u03bcl to below lower limit ) 22 in the tocilizumab group versus none in the placebo group .", "label": "", "metadata": {}, "score": "45.95369"}
{"text": "Studies of nonsteroidal anti - inflammatory drugs usu- ally report higher success rates than that seen in our study for conservative therapy .A possible explanation is the stringent long - term primary end point in our study com- pared with studies including a drug regimen and placebo , in which the effect is usually measured immediately after a well - specified short - term treatment period .", "label": "", "metadata": {}, "score": "46.398064"}
{"text": "Efficacy assessments .Percentages of patients achieving ( A ) ACR20 , ( B ) ACR50 and ( C ) ACR70 responses over time .All comparisons were tocilizumab plus DMARD vs placebo plus DMARD .", "label": "", "metadata": {}, "score": "46.68277"}
{"text": "PGI - S was only administered at V2 and PGI - I only at endpoint .Associations between the PGI - S or the PGI - I and the other assessments were analyzed by calculating Spearman rank correlation coefficients and performing analysis of variance ( ANOVA ) .", "label": "", "metadata": {}, "score": "46.73574"}
{"text": "The proportion of patients experienc- ing a flare during the 12 weeks was lower in the rilonacept group than in the placebo group ( 14.6 % versus 45.2 % ; P ?", "label": "", "metadata": {}, "score": "46.923508"}
{"text": "The resulting treatment failures reduced the success rate to 28 % for conservative treatment , 35 % for sham acupuncture , and 42 % for TCA .", "label": "", "metadata": {}, "score": "46.961258"}
{"text": "Patients entered into the placebo - controlled part of this study were only those who clearly demonstrated response to BUP TDS .Results indicated that more than 30 % of initial patients did not meet this criteria and did not respond to BUP TDS .", "label": "", "metadata": {}, "score": "47.348785"}
{"text": "Further , as noted above , the proportion of pa- tients who had withdrawn from the study at the 12-week analysis was smaller among those treated with rilonacept than among those treated with placebo .", "label": "", "metadata": {}, "score": "47.470062"}
{"text": "While the IPSS questionnaire is accepted as a critical component in BPH - LUTS research , the IPSS - QoL and BII ( assessments of symptom burden and impact ) are less frequently used .", "label": "", "metadata": {}, "score": "47.69326"}
{"text": "While the IPSS questionnaire is accepted as a critical component in BPH - LUTS research , the IPSS - QoL and BII ( assessments of symptom burden and impact ) are less frequently used .", "label": "", "metadata": {}, "score": "47.69326"}
{"text": "One factor is the recall period for the measures .The IPSS has a month recall period in which respondents are to recall and purportedly average their symptom severity over that month , whereas the PGI - S asks respondents to report current severity .", "label": "", "metadata": {}, "score": "48.029324"}
{"text": "One factor is the recall period for the measures .The IPSS has a month recall period in which respondents are to recall and purportedly average their symptom severity over that month , whereas the PGI - S asks respondents to report current severity .", "label": "", "metadata": {}, "score": "48.029324"}
{"text": "Study discontinuations due to adverse events occurred in 11 ( 4.8 % ) of the 229 Fampridine - SR - treated patients , and none of the 72 patient placebo group .", "label": "", "metadata": {}, "score": "48.103725"}
{"text": "Results : Success rates were 53.1 % for TCA , 51.0 % for sham acupuncture , and 29.1 % for conservative therapy .There was no difference between TCA and sham acupuncture ( relative risk , 1.01 [ CI , 0.87 to 1.17 ] ) .", "label": "", "metadata": {}, "score": "48.19502"}
{"text": "Nine patients in the placebo group had withdrawn from the study by week 12 , compared with only 1 in the rilonacept group ( P ? 0.015 by Fisher 's exact test ) , and this had increased to a total of 11 withdrawals in the placebo group and 3 in the rilonacept group at the end of double - blind treatment period at week 16 ( P ? 0.0377 by Fisher 's exact test ) .", "label": "", "metadata": {}, "score": "48.21502"}
{"text": "The high patient retention rate ( 87 % ) among DMARD refractory patients receiving adalimumab ( v 67 % for placebo ) indicated that study participants were willing to cope with occasional side effects as well as with self administration of the study drug to sustain improved disease control .", "label": "", "metadata": {}, "score": "48.608585"}
{"text": "This is in comparison to 17.3 % and 15.3 % of placebo patients who achieved ACR20 , respectively .Secukinumab was well - tolerated in both studies .", "label": "", "metadata": {}, "score": "48.61257"}
{"text": "The per - protocol analysis set consists of 611 patients : 200 who received TCA ( 32.7 % ) , 223 who received sham acupuncture ( 36.5 % ) , and 188 who received conservative therapy ( 30.8 % ) .", "label": "", "metadata": {}, "score": "48.92296"}
{"text": "At the end of two weeks , patients who responded to BUP TDS were assigned to the BUP TDS group or the placebo group for a two - week maintenance phase .", "label": "", "metadata": {}, "score": "48.94467"}
{"text": "Other secondary outcomes were TJC , SJC , a battery of disease activity and health assessments , including the disease activity score 28 ( DAS28 ) , ESR , and CRP .", "label": "", "metadata": {}, "score": "48.994545"}
{"text": "A high correlation between symptoms scores but a weak correlation with objective parameters ( including Qmax ) has been reported before in studies within the same BPH disease area as well as in other areas such as female stress incontinence .", "label": "", "metadata": {}, "score": "49.03327"}
{"text": "A high correlation between symptoms scores but a weak correlation with objective parameters ( including Qmax ) has been reported before in studies within the same BPH disease area as well as in other areas such as female stress incontinence .", "label": "", "metadata": {}, "score": "49.03327"}
{"text": "The composite pain responder criteria for fibromyalgia pain also reached statistical significance during Study MLN - MD-02 : 39 % and 46 % in the milnacipran 100 mg and 200 mg groups , respectively compared to 25 % for placebo .", "label": "", "metadata": {}, "score": "49.12467"}
{"text": "These contradictory results may be attributable to differences in study design , outcome measures , and acu- puncture schemes .Witt and colleagues ( 32 ) considered the reduction in WOMAC score after 8 weeks ( directly at the end of the treatment ) as the primary end point .", "label": "", "metadata": {}, "score": "49.142002"}
{"text": "HAQ Disability Index scores for adalimumab decreased significantly from the first evaluation to the end of the study .Decreases in HAQ scores at week 2 averaged 0.34 , 0.28 , and 0.30 for adalimumab 20 , 40 , and 80 mg , respectively , compared with an increase of +0.05 for placebo , indicating worsening of disability .", "label": "", "metadata": {}, "score": "49.273983"}
{"text": "The associations between PGI - S response at V2 and other patient - reported and clinical measures at V2 ( IPSS , IPSS - QoL , BII , and Qmax ) were evaluated using 2 types of analyses .", "label": "", "metadata": {}, "score": "49.285248"}
{"text": "The associations between PGI - S response at V2 and other patient - reported and clinical measures at V2 ( IPSS , IPSS - QoL , BII , and Qmax ) were evaluated using 2 types of analyses .", "label": "", "metadata": {}, "score": "49.285248"}
{"text": "In FUTURE 1 , 64.9 % ( 150 mg ) , 60.4 % ( 75 mg ) , and 58.4 % ( placebo ) of patients reported an AE .", "label": "", "metadata": {}, "score": "49.366726"}
{"text": "The changes in the TCA and sham acupuncture groups were much more distinct than those measured in the conservative therapy group ( ? 2.3 [ CI , ? 2.5 to ? 2.0 ] , ? 2.1 [ CI , ? 2.3 to ? 1.8 ] , and ? 1.2 [ CI , ? 1.5 to ? 0.9 ] , respectively ) .", "label": "", "metadata": {}, "score": "49.498497"}
{"text": "Mean change in Qmax values for participants who responded on the PGI - I as improved or\"Better \" were significantly higher than those for participants who responded as \" No Change \" or classified as responding \" Worse \" .", "label": "", "metadata": {}, "score": "49.614212"}
{"text": "Mean change in Qmax values for participants who responded on the PGI - I as improved or\"Better \" were significantly higher than those for participants who responded as \" No Change \" or classified as responding \" Worse \" .", "label": "", "metadata": {}, "score": "49.614212"}
{"text": "The investigator judged the relationship of the death to the study drug as being unlikely .The high incidence of laboratory abnormalities - nearly 50 % overall - can be attributed to the automatic reporting of these events whenever changes in CTC grade occurred ( which may have been small departures from normal ranges ) , regardless of their clinical relevance .", "label": "", "metadata": {}, "score": "49.647423"}
{"text": "Significant divergence between groups was detected as early as week 4 , with 4.9 % of the rilonacept - treated patients reporting a flare , versus 26.2 % of the placebo - treated patients ( P ?", "label": "", "metadata": {}, "score": "49.649208"}
{"text": "Success rates were 53.1 % for TCA , 51.0 % for sham acupuncture , and 29.1 % for conservative therapy .There was no difference between TCA and sham acupuncture ( relative risk , 1.01 [ CI , 0.87 to 1.17 ] ) .", "label": "", "metadata": {}, "score": "49.674652"}
{"text": "The proportions of patients who discontinued previous treatment with anti - TNF or non - biological DMARD were similar between groups , as was the proportion of patients currently receiving methotrexate as active DMARD ( 86.3 % tocilizumab , 86.8 % placebo ) .", "label": "", "metadata": {}, "score": "49.744476"}
{"text": "It is not at all surprising that patients using any pain medication would respond better than patients receiving placebo .Authors note that European Medicines Agency guidelines regarding chronic pain recommend comparing active treatment versus placebo to prove efficacy .", "label": "", "metadata": {}, "score": "49.78764"}
{"text": "RESULTS .Demographic and baseline characteristics .The demographic and baseline characteristics of the study population ( table 1 ) were similar for all treatment groups .", "label": "", "metadata": {}, "score": "49.88286"}
{"text": "At week fourteen , 66 % and 67 % of subjects in the golimumab 50 mg and 100 mg arms , respectively , were DAS28 responders , compared with 24 % of subjects in the placebo arm ( p less than 0.001 ) .", "label": "", "metadata": {}, "score": "49.90364"}
{"text": "Safety .Table 3 presents an overview of AE during double - blind treatment .Twenty - seven patients ( 6.6 % ) withdrew from the treatment because of AE in the tocilizumab group versus eight patients ( 3.9 % ) in the placebo group .", "label": "", "metadata": {}, "score": "49.917496"}
{"text": "Of the 289 subjects entered , 32 % discontinued BUP TDS treatment during the initial two - week run - in phase .Of the 189 patients who responded to BUP , 15.8 % discontinued the study : 7 in the BUP TDS group and 24 in the placebo group .", "label": "", "metadata": {}, "score": "50.060654"}
{"text": "Associations between the PGI - S or the PGI - I and the other assessments were analyzed by calculating Spearman rank correlation coefficients and performing analysis of variance ( ANOVA ) .", "label": "", "metadata": {}, "score": "50.11788"}
{"text": "In the tocilizumab group , the mean DAS28 decreased from 6.53 at baseline to 3.24 at week 24 .Furthermore , significantly greater proportions of patients in the tocilizumab versus the placebo group achieved both LDA and clinical remission at all time points from week 4 onwards ( figure 3C , D ) .", "label": "", "metadata": {}, "score": "50.122498"}
{"text": "A slightly different patient global assessment of improvement has been included before in a placebo - controlled 1-year study assessing changes to mono - therapy or combination - therapy with an alpha - blocker and/or 5 alpha - reductase - inhibitor in men with BPH - LUTS [ 19 ] .", "label": "", "metadata": {}, "score": "50.231014"}
{"text": "A slightly different patient global assessment of improvement has been included before in a placebo - controlled 1-year study assessing changes to mono - therapy or combination - therapy with an alpha - blocker and/or 5 alpha - reductase - inhibitor in men with BPH - LUTS [ 19 ] .", "label": "", "metadata": {}, "score": "50.231014"}
{"text": "Before the study , all patients had used at least one DMARD ( mean 3.75 ) , with more than half ( 50.3 % ) having used from four to eight different DMARDs .", "label": "", "metadata": {}, "score": "50.26396"}
{"text": "It should be noted that these analyses were conducted to support the validity of the PGI - S and PGI - I and not to explore whether ethnic / racial groups differ in perception of severity or response to treatment .", "label": "", "metadata": {}, "score": "50.318172"}
{"text": "It should be noted that these analyses were conducted to support the validity of the PGI - S and PGI - I and not to explore whether ethnic / racial groups differ in perception of severity or response to treatment .", "label": "", "metadata": {}, "score": "50.318172"}
{"text": "According to the recommendations of the OsteoArthritis Research Society International ( 21 ) , success rates were calculated according to a change of at least 36 % from baseline WOMAC scores at 13 and 26 weeks after the start of treatment ( 22 ) .", "label": "", "metadata": {}, "score": "50.369198"}
{"text": "Random - effects multivariate logistic regression analysis confirmed the existence of strong overall differences among treatment groups ( P ? 0.001 for global comparison ) .", "label": "", "metadata": {}, "score": "50.3984"}
{"text": "By week 2 , all adalimumab groups attained significant mean reductions in SJC from baseline-4.6 , 5.0 , and 5.4 for adalimumab 20 , 40 , and 80 mg , respectively , compared with 0.9 for placebo .", "label": "", "metadata": {}, "score": "50.41653"}
{"text": "Page 8 . point period , there was a 21.4 % dropout rate in the placebo group compared to a 2.4 % dropout rate in the rilonacept group .", "label": "", "metadata": {}, "score": "50.63005"}
{"text": "In addition , as noted above , a higher proportion of placebo - treated patients withdrew from the study and thus may have terminated their allopurinol treatment .", "label": "", "metadata": {}, "score": "50.890205"}
{"text": "As in other randomised clinical trials , the study has similar limitations including restrictions on patient enrolment , lack of major comorbidities represented among the treated patients , limited use of additional medications and strict dosing regimens .", "label": "", "metadata": {}, "score": "51.084625"}
{"text": "Correlation between PGI - I and other BPH Measures ( change from baseline ) in all patients .Overall and pairwise comparison p - values are from analysis of variance without adjusting for covariates .", "label": "", "metadata": {}, "score": "51.118618"}
{"text": "No patients in the placebo group tested positive to anti - dsDNA antibodies .No patients developed lupus - like syndrome , and no malignancies were reported .", "label": "", "metadata": {}, "score": "51.219067"}
{"text": "Safety Numbers of adverse events were comparable for the 3 groups .One hundred seventy - nine adverse events were re- corded in the TCA group , 177 were recorded in the sham group , and 159 were recorded in the conservative therapy group .", "label": "", "metadata": {}, "score": "51.243332"}
{"text": "The ITT population included all but the previously mentioned participant with Felty 's syndrome , who was withdrawn from the study after receiving one sc injection of adalimumab 20 mg .", "label": "", "metadata": {}, "score": "51.354843"}
{"text": "The sensitivity analyses for the success rate studied included adjustment for the additional covariates , baseline WOMAC score , use of physiotherapy , and extension of treatment period .", "label": "", "metadata": {}, "score": "51.41806"}
{"text": "A two - sided Fisher 's exact test was used to determine p values for ACR responses , LDA and DAS28 remission differences between groups at each time point .", "label": "", "metadata": {}, "score": "51.447365"}
{"text": "Mean values of total cholesterol , low - density lipoprotein cholesterol , high - density lipoprotein cholesterol and triglycerides increased in the tocilizumab group from baseline to the end of the study , while the placebo group showed little change over time .", "label": "", "metadata": {}, "score": "51.64791"}
{"text": "The study has two phases .The acute phase study lasts for eight weeks and compares the efficacy of escitalopram and placebo on depressive symptoms in bipolar depression .", "label": "", "metadata": {}, "score": "51.698757"}
{"text": "Demographic and baseline characteristics were summarised by descriptive statistics , and treatment group comparability at baseline was determined using appropriate statistical tests .Efficacy analyses were performed for the intention to treat ( ITT ) population , defined as all randomised patients who received at least one double blind injection of study drug and for whom any assessment of efficacy under double blind conditions was available .", "label": "", "metadata": {}, "score": "51.821766"}
{"text": "Methods The rapid onset and systemic efficacy study was a 24-week , randomised , double - blind trial .Significant improvements associated with tocilizumab versus placebo were seen in routine assessment of patient index data responses , EULAR good response , DAS28 and percentages of patients achieving low disease activity and clinical remission ( based on DAS28 ) .", "label": "", "metadata": {}, "score": "51.855026"}
{"text": "The population is intended to be representative of the patients treated for bipolar depression in ordinary specialist care .Patients must have a MADRS score of at least 20 at baseline .", "label": "", "metadata": {}, "score": "51.972992"}
{"text": "The SF-12 physical subscale at week 26 was also greater with TCA and sham acupuncture than with conservative ther- apy .Differences in the SF-12 mental subscale could not be detected among the treatment groups ( Table 3 ) .", "label": "", "metadata": {}, "score": "52.379887"}
{"text": "Fifty serious adverse events were reported ( 23 in 20 patients in the TCA group , 9 in 9 patients in the sham acupuncture group , and 18 in 16 patients in the conservative therapy group ) .", "label": "", "metadata": {}, "score": "52.400352"}
{"text": "Page 8 . baseline values .However , our study has several limitations .Adherence to the predefined acupuncture schemes could not be monitored .The recruited patients assumedly had an interest in acupuncture , possibly introducing a selection effect .", "label": "", "metadata": {}, "score": "52.47273"}
{"text": "Statistically significant differences between the tocilizumab and placebo groups were not observed at day 7 for tender and swollen joint counts or physician 's global assessment of disease activity ( table 2 ) .", "label": "", "metadata": {}, "score": "52.585995"}
{"text": "BUP and placebo patches were identical in appearance and adhesive properties .Twice daily patients reported current pain on a 10-point scale .Authors evaluated the amount of BUP rescue medication taken and patients ' global satisfaction with treatment .", "label": "", "metadata": {}, "score": "52.70996"}
{"text": "It is difficult to analyse such data because patients in both groups had blood samples drawn while not fasting , and the two groups were not matched for dietary intake and baseline lipid profiles .", "label": "", "metadata": {}, "score": "52.74087"}
{"text": "A simple 1-item global questionnaire may , therefore , seem more applicable today .Evidence of the construct validity of the PGI - S and PGI - I for men with BPH - LUTS provided in this study indicates that the 2 instruments could be a valuable and useful tool for clinical studies and practice .", "label": "", "metadata": {}, "score": "52.74369"}
{"text": "In general , practitioner - patient contacts were less intense in the conservative therapy group than in the TCA and sham acupuncture groups .Conclusions : Compared with physiotherapy and as - needed anti- inflammatory drugs , addition of either TCA or sham acupuncture led to greater improvement in WOMAC score at 26 weeks .", "label": "", "metadata": {}, "score": "52.81272"}
{"text": "Individual patient shifts in lipid parameters from normal levels at baseline to levels above adult treatment panel III recommended thresholds 23 at the end of the study are also shown in the supplementary appendix ( table S6 ) , available online only .", "label": "", "metadata": {}, "score": "52.83202"}
{"text": "In men participating in clinical trials evaluating treatment for LUTS , evidence for the validity of the PGI - S and PGI - I was provided through the associations observed with other symptom and quality of life assessments , but not with peak flow rate severity or changes .", "label": "", "metadata": {}, "score": "52.946003"}
{"text": "The mixed - effects models used the likelihood ratio tests to assess differences among the 3 treatment groups .If the global test rejected the null hypothesis of no difference between all treatments , paired comparisons were per- formed between treatment groups in a second step , also using likelihood ratio tests .", "label": "", "metadata": {}, "score": "52.999214"}
{"text": "The mean DAS28 was 6.5 at baseline in both treatment groups .Most patients in both treatment groups reported using one background DMARD at baseline .", "label": "", "metadata": {}, "score": "53.01408"}
{"text": "A simple 1-item global questionnaire may , therefore , seem more applicable today .Conclusions .Evidence of the construct validity of the PGI - S and PGI - I for men with BPH - LUTS provided in this study indicates that the 2 instruments could be a valuable and useful tool for clinical studies and practice .", "label": "", "metadata": {}, "score": "53.039284"}
{"text": "The aim of this study was to provide evidence that supports the validity of these two 1-item questionnaires for LUTS suggestive of BPH by correlating them with other subjective and objective measures of symptom severity or changes in severity in tadalafil placebo - controlled studies .", "label": "", "metadata": {}, "score": "53.153957"}
{"text": "The aim of this study was to provide evidence that supports the validity of these two 1-item questionnaires for LUTS suggestive of BPH by correlating them with other subjective and objective measures of symptom severity or changes in severity in tadalafil placebo - controlled studies .", "label": "", "metadata": {}, "score": "53.153957"}
{"text": "At week twenty - four , PASI 75 improved to 56 % and 66 % ( golimumab 50 mg and 100 mg , respectively ) compared with 1 % for placebo ( p less than 0.001 ) .", "label": "", "metadata": {}, "score": "53.26493"}
{"text": "Patients not completing the 12 week trial ( that is , those who were withdrawn or required rescue ) despite fulfilling ACR criteria were considered non - responders .", "label": "", "metadata": {}, "score": "53.27664"}
{"text": "Correlation between PGI - S and other baseline BPH Measures in all patients .Overall and pairwise comparison p - values are from analysis of variance without adjusting for covariates .", "label": "", "metadata": {}, "score": "53.286304"}
{"text": "Efficacy .The mean number of acute gout flares per patient over the 12-week period ( primary end point ) was significantly lower in the rilonacept group ( 0.15 Figure 1 .", "label": "", "metadata": {}, "score": "53.34475"}
{"text": "Descriptive treatment group comparisons between groups receiving adalimumab and placebo were performed at week 12 using two sided Pearson 's \u03c7 2 tests and analysis of covariance ( ANCOVA ) .", "label": "", "metadata": {}, "score": "53.745346"}
{"text": "( 7 % ) versus 7 ( 10 % ) , respectively .Serious infections occurred in 4 ( 2 % ) patients in the adalimumab dose groups .", "label": "", "metadata": {}, "score": "53.82801"}
{"text": "No patients receiving placebo attained an ACR70 response .Maximal responses for the treatment groups receiving adalimumab 20 , 40 , and 80 mg were reached at week 12 ( 8 , 11 % ) , week 10 ( 9 , 13 % ) , and week 12 ( 6 , 8 % ) , respectively .", "label": "", "metadata": {}, "score": "53.864166"}
{"text": "Values are from V1-V2 , before enrolled into the single - blind placebo run in period .A total of 1692 men completed the PGI - S at V2 ( before the placebo run - in period ) and 1628 men completed the PGI - I at last visit .", "label": "", "metadata": {}, "score": "53.92211"}
{"text": "Pain composite responders were defined as individuals who achieved both a greater than or equal to 30 % reduction in pain from baseline and who rated themselves as \" very much improved \" or \" much improved \" on a Patient Global Impression of Change ( PGIC ) scale .", "label": "", "metadata": {}, "score": "53.93275"}
{"text": "In general , practitioner - patient contacts were less intense in the conservative therapy group than in the TCA and sham acupuncture groups .Compared with physiotherapy and as - needed anti - inflammatory drugs , addition of either TCA or sham acupuncture led to greater improvement in WOMAC score at 26 weeks .", "label": "", "metadata": {}, "score": "53.993176"}
{"text": "SD .RILONACEPT FOR GOUT FLARE PREVENTION879 .Page 5 .[ representing 6 total flares at 12 weeks ] ) compared to the placebo group ( 0.79 [ representing 33 total flares ] ) ( P ? 0.0011 ) ( Figure 2A ) .", "label": "", "metadata": {}, "score": "54.008965"}
{"text": "Hypotheses : .Escitalopram , given in addition to mood stabilising medications , is significantly more efficacious , measured by response and remission rates than placebo in bipolar depression ( the acute phase study ) .", "label": "", "metadata": {}, "score": "54.052788"}
{"text": "Clinical measures .Postvoid residual volume ( PVR ) and prostate - specific antigen ( PSA ) were assessed in all studies , but not consistently carried out at the V2 .", "label": "", "metadata": {}, "score": "54.053707"}
{"text": "All patients randomly allocated to receive adalimumab and who received at least one dose of adalimumab were included in the safety analyses .Vital signs and laboratory measures were described by statistical characteristics and by the frequency of abnormal values .", "label": "", "metadata": {}, "score": "54.11273"}
{"text": "Discussion .In men participating in clinical trials evaluating treatment for LUTS , evidence for the validity of the PGI - S and PGI - I was provided through the associations observed with other symptom and quality of life assessments , but not with peak flow rate severity or changes .", "label": "", "metadata": {}, "score": "54.229103"}
{"text": "These improvements were maintained through week twenty - four , with 52 % and 61 % of subjects receiving golimumab 50 mg and golimumab 100 mg , respectively , reaching ACR 20 , compared with 12 % of subjects receiving placebo ( p less than 0.001 ) .", "label": "", "metadata": {}, "score": "54.260384"}
{"text": "A loading dose of rilonacept ( 320 mg [ 2 doses of 2 ml ] ) or placebo was adminis- tered on study day 1 .", "label": "", "metadata": {}, "score": "54.300846"}
{"text": "Similar results were seen across race , ethnicity , and baseline severity ( moderate LUTS versus severe LUTS ) .Similar results were seen across race , ethnicity , and baseline severity .", "label": "", "metadata": {}, "score": "54.36236"}
{"text": "A proposed approach to recognise ' near - remission ' quantitatively without formal joint counts or laboratory tests : a patient self - report questionnaire routine assessment of patient index data ( RAPID ) score as a guide to a ' continuous quality improvement ' .", "label": "", "metadata": {}, "score": "54.381172"}
{"text": "Those who responded to escitalopram are re - randomised to continue taking placebo or escitalopram in unchanged doses .Sociodemographic variables include age , gender , previous and concomitant disorders , course and treatment of mental disorders , bipolar disorder type ( I or II ) , age of onset and history of psychotropic medication use .", "label": "", "metadata": {}, "score": "54.38667"}
{"text": "Patients taking no analgesics dur- ing the trial differed by treatment group : 162 in the TCA group ( 50.3 % ) , 202 in the sham acupuncture group ( 55.8 % ) , and 104 in the conservative therapy group ( 33.2 % ) .", "label": "", "metadata": {}, "score": "54.558475"}
{"text": "Efficacy assessment .Clinical and laboratory efficacy assessments were conducted at screening , baseline , and two week intervals .ACR core criteria were monitored at each study visit : TJC and SJC ; patient assessments of pain , disease activity , and disability ( Disability Index of the Health Assessment Questionnaire ( HAQ ) 48 ) ; doctor global assessment of disease activity ; ESR ; and CRP .", "label": "", "metadata": {}, "score": "54.832626"}
{"text": "The patient with raised ANA titres ( of grade 3 severity and a maximum titre of 1/1280 at the time of withdrawal ) was withdrawn because the investigator concluded that the condition was related to treatment with the study drug .", "label": "", "metadata": {}, "score": "54.944633"}
{"text": "Most liver enzyme elevations were single occurrences with no cases of drug - induced injury .In the tocilizumab group , 27.9 % of patients had neutrophil levels less than the lower limit of normal ( 1.96\u00d710 9 /l ) at some point during the study versus 4.0 % of patients in the placebo group .", "label": "", "metadata": {}, "score": "55.212883"}
{"text": "The PGI - I also was a secondary objective , with 1 assessment at endpoint .PGI - S assessed participants ' perception of symptom severity at V2 and was an exploratory parameter .", "label": "", "metadata": {}, "score": "55.2237"}
{"text": "The PGI - I also was a secondary objective , with 1 assessment at endpoint .PGI - S assessed participants ' perception of symptom severity at V2 and was an exploratory parameter .", "label": "", "metadata": {}, "score": "55.2237"}
{"text": "CRP and ESR values ( 59 mg / l and 52.2 mm/1st h , respectively ) substantially exceeded normal levels .Patient and doctor based assessments of disease activity and patient assessment of pain were 73.1 , 64.9 , and 71.7 , respectively .", "label": "", "metadata": {}, "score": "55.413834"}
{"text": "The aim of this study was to provide evidence of the validity of the 1-item Patient Global Impression of Severity ( PGI - S ) and Improvement ( PGI - I ) questionnaires for use as outcome measures in the treatment of BPH - LUTS .", "label": "", "metadata": {}, "score": "55.414536"}
{"text": "It was performed by an independent data review committee .The study management team , investigational staff and monitors remained blinded to individual patients ' treatment assignments .", "label": "", "metadata": {}, "score": "55.53289"}
{"text": "Relative efficiencies of physician / assessor global estimates and patient questionnaire measures are similar to or greater than joint counts to distinguish adalimumab from control treatments in rheumatoid arthritis clinical trials .", "label": "", "metadata": {}, "score": "55.55924"}
{"text": "Similar results were seen across race , ethnicity , and baseline severity .CONCLUSIONS : This study demonstrated patients ' overall perceptions of their severity and change in BPH - LUTS can be captured in a way that is simple , valid , and easily administered in a research setting or clinical practice .", "label": "", "metadata": {}, "score": "55.670975"}
{"text": "Blinded central telephone interviews were conducted in weeks 13 and 26 to record the main and secondary outcome measures ( SF-12 [ 14 ] and global patient assess- ment [ 23 ] ) .", "label": "", "metadata": {}, "score": "55.759075"}
{"text": "Patients in the acupuncture groups received treatment at each visit .The mean number of acu- puncture sessions was 12.5 in the TCA and sham groups .", "label": "", "metadata": {}, "score": "55.846893"}
{"text": "For each eligible patient , the practitioner called the randomization center and was immediately informed by fax of the patient 's treatment group .Outcomes The effect on pain and function was measured with the WOMAC score ( total score and the subscales standard- ized to 0 to 10 ) .", "label": "", "metadata": {}, "score": "55.8713"}
{"text": "Increased response rate with treatment was seen across all four major ( relapsing and progressive ) types of MS . .The mean increase in walking speed , compared to pre - treatment , for Fampridine - SR treated Timed Walk Responders was significantly greater at every visit during the treatment period , compared to both Fampridine - SR Timed Walk Non - Responders and placebo treated patients ( p less than 0.0001 ) .", "label": "", "metadata": {}, "score": "55.902664"}
{"text": "All adalimumab doses acted more rapidly and were more efficacious than placebo , with the 80 mg dose of adalimumab not providing any additional benefit over the 40 mg dose .", "label": "", "metadata": {}, "score": "55.98208"}
{"text": "Symptom severity at V2 as assessed by PGI - S and changes in symptoms as assessed by PGI - I at endpoint were moderately to highly correlated with scores from other BPH patient - reported measures .", "label": "", "metadata": {}, "score": "56.01503"}
{"text": "Symptom severity at V2 as assessed by PGI - S and changes in symptoms as assessed by PGI - I at endpoint were moderately to highly correlated with scores from other BPH patient - reported measures .", "label": "", "metadata": {}, "score": "56.01503"}
{"text": "In the TCA and sham acupuncture groups , 10 acu- puncture sessions administered over a 6-week period began 2 weeks after screening .Patients receiving acupuncture who met the criterion for partial success were also entitled to 5 additional treatment sessions .", "label": "", "metadata": {}, "score": "56.026237"}
{"text": "ACR response .At week 12 , 36 ( 51 % ) , 40 ( 57 % ) , and 39 ( 54 % ) patients treated with adalimumab 20 , 40 , and 80 mg , respectively , were ACR20 responders , compared with 7 ( 10 % ) placebo patients .", "label": "", "metadata": {}, "score": "56.12995"}
{"text": "Proportion of patients reporting gout flares through week 12 ( primary efficacy end point ) and % of patients with flare Treatment period Placebo group ( n ?", "label": "", "metadata": {}, "score": "56.204617"}
{"text": "Study drug utilization and adherence .The mean daily study doses of allopurinol were comparable be- tween treatment groups and were similar at 12 weeks ( mean ?", "label": "", "metadata": {}, "score": "56.301964"}
{"text": "6.31 placebo , 0.51 ? 1.82 rilonacept ( all P ? 0.05 by Wilcoxon 's rank sum test ) .Table 4 .Summary of adverse events No .", "label": "", "metadata": {}, "score": "56.310944"}
{"text": "Most study patients were women ( 68.8 % ) .Twenty - five percent of the patients were younger than age 55 years .There were no pretreatment differences among the 3 treatment groups with respect to demo- graphic characteristics , outcome variables ( Table 3 ) , dis- ease - specific characteristics , and medication use , suggesting that the randomization procedure produced comparable groups at baseline .", "label": "", "metadata": {}, "score": "56.324394"}
{"text": "Patient characteristics were assessed at V2 .Clinical measures .Postvoid residual volume ( PVR ) and prostate - specific antigen ( PSA ) were assessed in all studies , but not consistently carried out at the V2 .", "label": "", "metadata": {}, "score": "56.385292"}
{"text": "30 ml / minute ) , or current use of immuno- suppressive therapy ; pregnant or lactating women were also excluded .Eligible patients were randomized 1:1 to begin treat- ment with placebo or rilonacept 160 mg ( 2 ml ) administered subcutaneously once weekly for 16 weeks , and oral allopurinol RILONACEPT FOR GOUT FLARE PREVENTION 877 .", "label": "", "metadata": {}, "score": "56.416756"}
{"text": "Responders to this open - label treatment are then re - randomised double blind to escitalopram or placebo for the continuation study .The continuation phase study lasts for 32 weeks .", "label": "", "metadata": {}, "score": "56.43651"}
{"text": "The physicians checked the patients ' eligibility criteria during a screening examination .A screening telephone in- terview was done to record baseline WOMAC values , qual- ity of life ( 12-item Short - Form Health Survey [ SF-12 ] ) ( 14 ) , von Korff scores ( 15 ) , and use of analgesics .", "label": "", "metadata": {}, "score": "56.44094"}
{"text": "fore , 1007 patients were analyzed following intention - to- treat principles : 326 randomly assigned to TCA ( 32.4 % ) , 365 randomly assigned to sham acupuncture ( 36.2 % ) , and 316 randomly assigned to conservative therapy ( 31.4 % ) .", "label": "", "metadata": {}, "score": "56.46947"}
{"text": "Z Rheumatol .[ PMID : 8868149 ] 12 .Von Korff M , Ormel J , Keefe FJ , Dworkin SF .Grading the severity of chronic pain .", "label": "", "metadata": {}, "score": "56.630424"}
{"text": "Both apremilast treatment arms had a significant improvement in the ACR20 outcome versus placebo at 12 weeks .In the 20 mg twice daily arm and the 40 mg once daily arm , 43.5 % and 35.8 % of subjects reached ACR20 , respectively , compared to 11.8 % of subjects in the placebo arm .", "label": "", "metadata": {}, "score": "56.63233"}
{"text": "Patients treated with escitalopram who have not responded after eight weeks ( defined by at least 50 % reduction of MADRS score compared to baseline ) leave the study .", "label": "", "metadata": {}, "score": "56.65326"}
{"text": "Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis ( the BeSt study ) : a randomized , controlled trial .", "label": "", "metadata": {}, "score": "56.696312"}
{"text": "Patients were required to discontinue previous biological therapy ( eg , adalimumab , etanercept , infliximab , abatacept , anakinra , rituximab ) before randomisation .", "label": "", "metadata": {}, "score": "56.855915"}
{"text": "The drug was well tolerated .The most frequent adverse events were nausea , diarrhea and headache .Based on this data , Celgene expects to file a separate NDA in the U.S. for psoriasis and a combined PsA / psoriasis MAA submission in Europe in the second half of 2013 .", "label": "", "metadata": {}, "score": "56.89379"}
{"text": "Recent reports substantiate this outcome among patients receiving adalimumab monotreatment over a one and two year period .35 , 36 Nevertheless , these results need to be confirmed in large radiographic studies .", "label": "", "metadata": {}, "score": "57.012634"}
{"text": "Pain .[ PMID : 11240091 ] 24 .Felson DT , Anderson JJ , Lange ML , Wells G , LaValley MP .Should im- provement in rheumatoid arthritis clinical trials be defined as fifty percent or seventy percent improvement in core set measures , rather than twenty percent ?", "label": "", "metadata": {}, "score": "57.082756"}
{"text": "Study Design .The study was open to people with all types of MS , including primary - progressive , secondary - progressive , relapsing - remitting and progressive - relapsing .", "label": "", "metadata": {}, "score": "57.10231"}
{"text": "Berman and colleagues ( 33 ) compared TCA plus electrostimulation at 1 point with a sham procedure different from our scheme , both applied in addition to conservative therapy ( needle insertion at only 2 nonacu- puncture points combined with noninvasive mock needle placement at acupuncture points ) .", "label": "", "metadata": {}, "score": "57.130558"}
{"text": "This study demonstrated patients ' overall perceptions of their severity and change in BPH - LUTS can be captured in a way that is simple , valid , and easily administered in a research setting or clinical practice .", "label": "", "metadata": {}, "score": "57.142067"}
{"text": "While the construct validity demonstrated in the analysis presented in our paper is applicable to a population of men with BPH - LUTS , the validity of the PGI - S and PGI - I for men with other lower urinary tract symptoms has not been established .", "label": "", "metadata": {}, "score": "57.15177"}
{"text": "While the construct validity demonstrated in the analysis presented in our paper is applicable to a population of men with BPH - LUTS , the validity of the PGI - S and PGI - I for men with other lower urinary tract symptoms has not been established .", "label": "", "metadata": {}, "score": "57.15177"}
{"text": "The primary analysis was also ad- justed for the number of affected knees ( fixed effects , 2 levels ) .Relative risks and absolute risk differences were cal- culated for the unadjusted success rates .", "label": "", "metadata": {}, "score": "57.282234"}
{"text": "Main end points were the WOMAC pain and function scores at week 8 .Another recent study ( 34 ) com- pared acupuncture with electrostimulation versus placebo acupuncture ( without needle insertion ) .", "label": "", "metadata": {}, "score": "57.299694"}
{"text": "Blinding between TCA and sham acupuncture was successful , the number of patients who left the study was kept low , and homogeneous treatment groups could be created with respect to demographic characteristics and Table 4 . 326 ) Sham Acupuncture Group ( n ?", "label": "", "metadata": {}, "score": "57.32917"}
{"text": "In Ger- the trials were poorly designed , none included long - term follow - up of more than 3 months , sample sizes were often too small , and there were relevant losses to follow - up or raters were not blinded .", "label": "", "metadata": {}, "score": "57.345947"}
{"text": "Overall , the different urinary symptoms provided as examples in the PGI - S and PGI - I were not meant to be exhaustive of all urinary symptoms or restrictive to BPH , but aimed at providing the patient with examples of common urinary symptoms he could experience .", "label": "", "metadata": {}, "score": "57.390697"}
{"text": "Overall , the different urinary symptoms provided as examples in the PGI - S and PGI - I were not meant to be exhaustive of all urinary symptoms or restrictive to BPH , but aimed at providing the patient with examples of common urinary symptoms he could experience .", "label": "", "metadata": {}, "score": "57.390697"}
{"text": "Measurement Instruments / Methods : .Ten - point numeric rating scale , to measure pain .Five - point Likert scale , to measure patients ' global satisfaction with treatment .", "label": "", "metadata": {}, "score": "57.56363"}
{"text": "Janssen issued results from a phase III trial of STELARA ( ustekinumab ) for active psoriatic arthritis .Patients were na\u00efve to treatment with anti - TNF - alpha therapies and/or IL-12/23 inhibitors .", "label": "", "metadata": {}, "score": "57.58286"}
{"text": "It should be noted that at baseline , more than half of the patients had AEs attributable to the disease state or to concomitant drugs .", "label": "", "metadata": {}, "score": "57.703163"}
{"text": "Kaplan - Meier analysis ( Figure 2B ) revealed that the median time to first gout flare in the placebo group ( estimated at 77 days ) was significantly earlier ( P ? 0.001 ) than that in the rilonacept group , for which the median time to flare could not be estimated over the study period .", "label": "", "metadata": {}, "score": "57.799"}
{"text": "Reasons for the 2 ( 3 % ) placebo withdrawals were AEs ( vasculitis / paralysis / pain ) and lack of efficacy .A greater proportion of patients in the placebo group ( 21 , 30 % ) required rescue during the 12 week study period because of uncontrolled disease activity than those receiving adalimumab ( 17 , 7.9 % ) .", "label": "", "metadata": {}, "score": "57.810375"}
{"text": "The most common adverse events overall were infections ( 14.6 % and 26.2 % in the rilona- cept and placebo groups , respectively ) and musculo- skeletal disorders ( 14.6 % and 21.4 % , respectively ) .", "label": "", "metadata": {}, "score": "57.86997"}
{"text": "The incidence of all- cause and treatment - related adverse events was similar in the 2 treatment groups ( Table 4 ) , and no deaths or serious infectious adverse events were reported .", "label": "", "metadata": {}, "score": "57.89531"}
{"text": "In study FMS-031 there were 488 evaluable subjects for the fibromyalgia syndrome analysis and 491 evaluable subjects for the fibromyalgia pain analysis .A statistically significant number of subjects treated with milnacipran during Study MLN - MD-02 met the composite syndrome responder criteria : 25 % and 26 % for the milnacipran 100 mg and 200 mg groups compared to 13 % for placebo .", "label": "", "metadata": {}, "score": "57.977646"}
{"text": "Antoni C , Kalden JR .Combination therapy of the chimeric monoclonal anti - tumour necrosis factor alpha antibody ( infliximab ) with methotrexate in patients with rheumatoid arthritis .", "label": "", "metadata": {}, "score": "58.12429"}
{"text": "RESULTS Recruitment Of 1531 screened patients , 492 could not be included in the study , mainly because they did not meet all eligibil- ity criteria ( Figure ) .", "label": "", "metadata": {}, "score": "58.128853"}
{"text": "Moreover , the assess- ment was done by the patients themselves using question- naires instead of by blinded telephone interviewers as in our study .Despite a similar basic concept of sham acu- puncture and TCA , differences in the choice of acupunc- ture points might have influenced the results .", "label": "", "metadata": {}, "score": "58.13562"}
{"text": "Patients who received rescue therapy and patients who did not have data required to assess efficacy outcomes at week 24 were classified as non - responders .", "label": "", "metadata": {}, "score": "58.215195"}
{"text": "Jespers LS , Roberts A , Mahler SM , Winter G , Hoogenboom HR .Guiding the selection of human antibodies from phage display repertoires to a single epitope of an antigen .", "label": "", "metadata": {}, "score": "58.326546"}
{"text": "Patient assessed outcomes such as functional status ( HAQ ) , RA related pain , and global disease activity significantly improved over the course of treatment with adalimumab .", "label": "", "metadata": {}, "score": "58.380127"}
{"text": "Some events were seen more frequently in the Fampridine - SR group ( insomnia , fatigue , back pain , balance disorder ) while upper respiratory infection was more common in the placebo group .", "label": "", "metadata": {}, "score": "58.437515"}
{"text": "Laboratory parameters .In the tocilizumab group , mean ALT , AST and total bilirubin levels increased by week 4 and generally remained elevated to week 24 , but remained within normal ranges .", "label": "", "metadata": {}, "score": "58.438362"}
{"text": "Two AEs occurred in adalimumab patients with 10 % or greater frequency than with placebo .None of the commonly reported treatment emergent AEs showed a dose - response relationship to adalimumab .", "label": "", "metadata": {}, "score": "58.502563"}
{"text": "Two patients in each group reported adverse events that were defined as severe by the investigators , with a total of 6 severe adverse events .", "label": "", "metadata": {}, "score": "58.531467"}
{"text": "For the acute study , response and remission rates as assessed by the MADRS are the primary outcome measures .CGI - Improvement and IDS - SR are secondary outcome measures .", "label": "", "metadata": {}, "score": "58.556587"}
{"text": "The patients knew whether they were in the conserva- tive therapy group but were blinded to TCA versus sham acupuncture .The investigators were not blinded to treat- ment group , but the person doing the telephone interviews for end point measurement was blinded to treatment as- signment .", "label": "", "metadata": {}, "score": "58.70478"}
{"text": "Off site self administration of the study drug continued throughout the study , with the exception of study visits , during which patients self administered adalimumab or placebo under supervision of study personnel .", "label": "", "metadata": {}, "score": "58.75876"}
{"text": "The proportion of patients achieving the primary end point ( ?36 % improvement on a standardized measure of pain and function ) was 53.1 % for traditional Chinese acupuncture , 51.0 % for sham acu- puncture ( blinded comparison ) , and 29.1 % for medical treatment ( nonblinded comparisons ) .", "label": "", "metadata": {}, "score": "58.9729"}
{"text": "While 26.2 % of placebo - treated patients reported multiple flares by week 16 , no Figure 2 .A , Mean number of gout flares per patient through week 22 ( end of the followup period ) , by treatment group .", "label": "", "metadata": {}, "score": "58.981136"}
{"text": "Clinically significant improvements occurred in several haematological laboratory values in adalimumab patients , including increased haemoglobin , packed cell volume , and percentages of lymphocytes as well as decreased platelet counts , fibrinogen levels , and percentages of neutrophils ( data not shown ) .", "label": "", "metadata": {}, "score": "59.053932"}
{"text": "In gout patients who are starting urate - lowering therapy and are thus at increased risk of gout attacks , rilonacept substantially reduced the occurrence of acute gout flares compared to placebo , as calculated on the basis of both the number of flares and the proportion of patients with flares .", "label": "", "metadata": {}, "score": "59.076103"}
{"text": "15 % of patients in either treatment group .\u00b6 Adverse events by high - level term ( Medical Dictionary for Regulatory Activities ; version 10 ) independent of relationship to study drug and occurring in ?", "label": "", "metadata": {}, "score": "59.11518"}
{"text": "Schattenkirchner M , Kr\u00fcger K , Sander O , Rau R , Kroot EJ , Riehl M , et al .Efficacy and tolerability of weekly subcutaneous injections of the fully human anti - TNF - antibody D2E7 in patients with rheumatoid arthritis .", "label": "", "metadata": {}, "score": "59.116684"}
{"text": "In this study , we also saw improvements in measures of leg strength and spasticity compared to the placebo group .In particular , even the Fampridine - SR group that did not show a consistent walking improvement still showed a statistically significant improvement in leg strength compared to the placebo group .", "label": "", "metadata": {}, "score": "59.11856"}
{"text": "The anxiety was considered probably related to treatment .A focal seizure , observed during the sepsis , was considered possibly related to treatment .An additional 13 patients in the Fampridine - SR - treated group experienced various serious adverse events but none of these led to discontinuation from treatment and none was considered related to treatment .", "label": "", "metadata": {}, "score": "59.14151"}
{"text": "Maini RN , St Clair EW , Breedveld F , Furst D , Kalden J , Weisman M , et al .Infliximab ( chimeric anti - tumour necrosis factor \u03b1 monoclonal antibody ) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate : a randomized phase III trial .", "label": "", "metadata": {}, "score": "59.178276"}
{"text": "Mean lipid levels increased in patients treated with tocilizumab compared with placebo , but the clinical relevance of these lipid elevations is unclear in the RA population at this time .", "label": "", "metadata": {}, "score": "59.188126"}
{"text": "Correlation between PGI - S and other baseline BPH Measures across race , ethnicity and baseline severity .Asian : from the 2 studies conducted in Asia ; Caucasian : from the 2 studies conducted outside Asia .", "label": "", "metadata": {}, "score": "59.19116"}
{"text": "The study will compare the occurrence of syndromal and subsyndromal relapses , mixed states , mania , hypomania , and \" rapid cycling \" in a seven months ' maintenance study following response to acute phase treatment .", "label": "", "metadata": {}, "score": "59.240593"}
{"text": "Success rates were analyzed by random - effects logistic regression models .Treatment was coded as a categorical variable with 3 levels , and 35 regional clusters of practition- ers were considered as random effects .", "label": "", "metadata": {}, "score": "59.25711"}
{"text": "They are typically used in knee pain treatment and have been previously used in osteoarthritis clinical trials ( Berman et al ., 2004 ; Cheng , 1987 ; Scharf et al . , 2006 ; Stux , 1997 ; Witt et al . , 2005 ) .", "label": "", "metadata": {}, "score": "59.260513"}
{"text": "By week 24 , all patients receiving placebo were crossed over to receive STELARA .Improvement in signs and symptoms continued to increase after week 24 , with 55.7 % and 60.3 % of patients in the STELARA 45 mg and STELARA 90 mg groups , respectively , demonstrating ACR 20 response at week 52 .", "label": "", "metadata": {}, "score": "59.327744"}
{"text": "Only patients for whom treatment had failed with at least one traditional DMARD were eligible .Exclusion criteria included joint surgery within two months before screening or an episode of infection requiring admission to hospital within 30 days before study entry .", "label": "", "metadata": {}, "score": "59.338997"}
{"text": "In addition , patients were assessed for flares during the 6-week followup period after the last dose of study drug administered during the blinded treatment period .", "label": "", "metadata": {}, "score": "59.400772"}
{"text": "Overall , 35 % of patients were receiving adjuvant chemotherapy , 18 % were receiving hormone treatment , and 9 % had had radiotherapy .Eligible patients had received insufficient pain relief from opioid regimens used before the study .", "label": "", "metadata": {}, "score": "59.486633"}
{"text": "There was a statistically significant improvement in the MSWS-12 score for walking Responders compared to Non - responders ( p less than 0.001 ) .In addition , the mean scores on all 12 questions in the MSWS-12 were better for the Responder group than the Non - responder group .", "label": "", "metadata": {}, "score": "59.503105"}
{"text": "14 Patients were randomly assigned 2:1 to receive tocilizumab 8 mg / kg intravenously every 4 weeks plus stable antirheumatic therapy including DMARD ( tocilizumab group ) or placebo intravenously every 4 weeks plus DMARD ( placebo group ) .", "label": "", "metadata": {}, "score": "59.748207"}
{"text": "Methods .Visit 2 ( V2 [ beginning of a 4-week placebo lead - in period ] ) and endpoint assessments included International Prostate Symptom Score ( IPSS ) , IPSS Quality of Life Index ( IPSS - QoL ) , BPH Impact Index ( BII ) , and peak urine flow ( Qmax ) .", "label": "", "metadata": {}, "score": "59.809467"}
{"text": "Correlation between PGI - I and other BPH Measures ( change from baseline ) across race , ethnicity and baseline severity .Asian : from the 2 studies conducted in Asia ; Caucasian : from the 2 studies conducted outside Asia .", "label": "", "metadata": {}, "score": "59.83362"}
{"text": "Two randomized , controlled trials using TCA and sham acupuncture in patients with osteoarthritis of the knee ( 32 , 33 ) reported results similar to those of our study .", "label": "", "metadata": {}, "score": "59.83539"}
{"text": "For other continuous variable end point inferential analyses , Stu- dent 's t - test was used .P values ( 2-sided ) less than 0.05 were considered significant .", "label": "", "metadata": {}, "score": "59.855354"}
{"text": "Page 4 . only ?60 - 70 % of the patients during the study treat- ment period ( observed data 62.5 % in the placebo group , 73.7 % in the rilonacept group at week 12 ; 58.1 % in the placebo group , 56.8 % in the rilonacept group at week 16 ) .", "label": "", "metadata": {}, "score": "59.85768"}
{"text": "O'Dell JR , Leff R , Paulsen G , Haire C , Mallek J , Eckhoff PJ , et al .Treatment of rheumatoid arthritis with methotrexate and hydroxychloroquine , methotrexate and sulfasalazine , or a combination of the three medications .", "label": "", "metadata": {}, "score": "59.8658"}
{"text": "While in the global impression scales implemented in the tadalafil clinical studies and validated here , examples of urinary symptoms were provided based on the symptoms in the IPSS questionnaire [ 3 ] , in addition to a few other symptoms .", "label": "", "metadata": {}, "score": "59.92955"}
{"text": "While in the global impression scales implemented in the tadalafil clinical studies and validated here , examples of urinary symptoms were provided based on the symptoms in the IPSS questionnaire [ 3 ] , in addition to a few other symptoms .", "label": "", "metadata": {}, "score": "59.92955"}
{"text": "Long - term use of the fully human anti - TNF antibody D2E7 in combination with methotrexate in active rheumatoid arthritis .Arthritis Rheum 2000 ; 43 : S238 ( abstr 968 ) .", "label": "", "metadata": {}, "score": "59.99301"}
{"text": "No efficacy assessments under double blind conditions were available for this patient .The closure principle was applied to take multiplicity of testing into account .", "label": "", "metadata": {}, "score": "60.00477"}
{"text": "With current approaches to gout flare prophy- laxis using colchicine or NSAIDs , reported flare rates have ranged from 22 % to 33 % ( 6,18,19 ) , and up to 14 % of patients experience multiple flares during initiation of urate - lowering therapy ( 6 ) .", "label": "", "metadata": {}, "score": "60.02583"}
{"text": "The incidence of \" mood switching \" ( defined as development of mixed episodes , mania , or hypomania according to DSM - IV criteria do not differ significantly between escitalopram and placebo in either the acute or the continuation phases .", "label": "", "metadata": {}, "score": "60.15766"}
{"text": "A subset of patients with CRP levels of 95.24 nmol / l or greater who received one or more administration of study drug and who agreed to participate in an ancillary substudy had additional assessments on days 3 and 7 to measure early response on disease activity control .", "label": "", "metadata": {}, "score": "60.191444"}
{"text": "[ PMID : 9751088 ] 25 .Lachin JM .Sample size determinants for r X c comparative trials .Biometrics .[ PMID : 884194 ]", "label": "", "metadata": {}, "score": "60.21476"}
{"text": "Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis .Comparison with the preliminary American College of Rheumatology and the World Health Organization / International League Against Rheumatism Criteria .", "label": "", "metadata": {}, "score": "60.221283"}
{"text": "The PGI - I was administered once at the end - of - study visit ( Week 12 or the last visit ) .PGI - S is a 1-item questionnaire designed to assess patient 's impression of disease severity .", "label": "", "metadata": {}, "score": "60.31693"}
{"text": "The PGI - I was administered once at the end - of - study visit ( Week 12 or the last visit ) .PGI - S is a 1-item questionnaire designed to assess patient 's impression of disease severity .", "label": "", "metadata": {}, "score": "60.31693"}
{"text": "Compared with placebo , all adalimumab groups had consistently better ACR responses and improvements in ACR core criteria from baseline .Overall , adalimumab was safe and well tolerated at all doses .", "label": "", "metadata": {}, "score": "60.34266"}
{"text": "Surprisingly , no differences were observed between the TCA and sham acupuncture groups .Superiority of TCA and sham acupuncture over conservative therapy and no detectable difference between TCA and sham acupunc- ture also held true for all secondary end points .", "label": "", "metadata": {}, "score": "60.346127"}
{"text": "For patients with impaired renal function , the initial daily dose of allopurinol was adjusted as recommended by Hande et al ( 16 ) , based on estimated creatinine clearance .", "label": "", "metadata": {}, "score": "60.424595"}
{"text": "Study design and participants .This was a secondary analysis of data from 4 clinical trials .Details of the study designs and populations have previously been published [ 12 - 15 ] .", "label": "", "metadata": {}, "score": "60.549095"}
{"text": "Additionally , serum was evaluated for the presence of antinuclear antibodies ( ANAs ) , anti - double stranded DNA ( anti - dsDNA ) antibodies ( if ANA levels were increased from baseline ) , and serum anti - adalimumab antibodies .", "label": "", "metadata": {}, "score": "60.593105"}
{"text": "Clinical trials with other sc administered biological agents in patients with RA reported injection site reactions of 37 % ( etanercept ) 28 and more than 70 % ( anakinra ) .", "label": "", "metadata": {}, "score": "60.602097"}
{"text": "One year treatment results of the fully human anti - TNF antibody D2E7 in combination with methotrexate in active rheumatoid arthritis .Ann Rheum Dis 2000 ; 59 ( suppl ) : 152 ( abstr POS-370 ) .", "label": "", "metadata": {}, "score": "60.716194"}
{"text": "We believe this is an important finding to consider when designing and interpreting outcomes of randomised clinical trials .Safety findings in this study were consistent with the known safety profile of tocilizumab .", "label": "", "metadata": {}, "score": "60.7312"}
{"text": "Rau R , Herborn G , Sander O , van de Putte LBA , van Riel PL , den Broeder AA , et al .Long - term treatment with the fully human anti - TNF - antibody D2E7 slows radiographic disease progression in rheumatoid arthritis .", "label": "", "metadata": {}, "score": "60.913666"}
{"text": "The incidence of \" mood switching \" ( defined as development of mixed episodes , mania , or hypomania according to DSM - IV criteria ) do not differ significantly between escitalopram and placebo in either the acute or the continuation phases .", "label": "", "metadata": {}, "score": "60.91828"}
{"text": "Assessments .The primary efficacy endpoint was the ACR50 response at week 24 .21 In the substudy , additional efficacy assessments for the early response on disease activity control included CRP levels on days 3 and 7 ; joint counts , patient and investigator global assessment of disease activity , patient pain assessment , MDHAQ and ESR on day 7 .", "label": "", "metadata": {}, "score": "60.932644"}
{"text": "Definitions Response : at least a 50 % reduction of the baseline MADRS score at the end of phase 1 if the patient has completed at least four weeks of the study .", "label": "", "metadata": {}, "score": "60.97179"}
{"text": "One 83-year - old woman in the TCA group died of a myocardial infarction during the study .The investigator saw no causal relationship between her death and the treat- ment .", "label": "", "metadata": {}, "score": "61.004143"}
{"text": "Significantly fewer flares were observed in the rilonacept - treated patients as early as 4 weeks after initiation of treatment ( P ? 0.007 ) , the earliest prespecified analysis time point .", "label": "", "metadata": {}, "score": "61.13611"}
{"text": "Arnett FC , Edworthy SM , Bloch DA , McShane DJ , Fries JF , Cooper NS , et al .The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis .", "label": "", "metadata": {}, "score": "61.252968"}
{"text": "Differing provisions from the publisher 's actual policy or licence agreement may be applicable .\" Phase II study involved 83 patients starting allopurinol ( 42 in the placebo group and 41 in the active treatment group ) .", "label": "", "metadata": {}, "score": "61.349266"}
{"text": "Thirty - two patients declined further participation immedi- ately after randomization and were excluded from the analy- sis because no measurements were available ( 28 ) .", "label": "", "metadata": {}, "score": "61.368668"}
{"text": "Time to serious infections in the tocilizumab group ranged from day 32 to day 170 after the start of therapy ( see supplementary appendix table S4 , available online only ) .", "label": "", "metadata": {}, "score": "61.430244"}
{"text": "Concomitant treatment with colchicine or non-steroidal antiinflammatory drugs ( NSAIDs ) to prevent gout flares ( prophylaxis ) is recommended during the first several months of urate - lowering therapy ( 2,6 ) .", "label": "", "metadata": {}, "score": "61.482445"}
{"text": "The 4 studies were in compliance with the Helsinki Declaration .In each study , participants were screened at V1 .In all 4 studies , there was a 2- ( Study 3 , LVHB ) or 4-week screening / washout period ( V1-V2 ) , a 4-week placebo lead - in period ( V2-V3 ) , and a 12-week double - blinded treatment period ( V3 to last visit ) .", "label": "", "metadata": {}, "score": "61.5067"}
{"text": "Am J Obstet Gynecol 2003 , 189 : 98 - 101 .PubMed View Article .Srikrishna S , Robinson D , Cardozo L : Validation of the Patient Global Impression of Improvement ( PGI - I ) for urogenital prolapse .", "label": "", "metadata": {}, "score": "61.57975"}
{"text": "Patients in the placebo group were switched to adalimumab 40 mg .Patients completing the 40 week period entered an open label continuation period , during which they received the same weekly doses of 40 mg adalimumab for another year .", "label": "", "metadata": {}, "score": "61.58793"}
{"text": "( Tables 3 and 5 ) .The association with the clinical parameter , peakflow ( Qmax ) , was weak both at V2 and endpoint ( Tables 2 and 4 ) .", "label": "", "metadata": {}, "score": "61.612926"}
{"text": "( Tables 3 and 5 ) .The association with the clinical parameter , peakflow ( Qmax ) , was weak both at V2 and endpoint ( Tables 2 and 4 ) .", "label": "", "metadata": {}, "score": "61.612926"}
{"text": "The aim of the current study was to evaluate further the efficacy and tolerability of tocilizumab for 6 months for the first time in a US patient population with moderate to severe active RA who had an inadequate clinical response to DMARD .", "label": "", "metadata": {}, "score": "61.630733"}
{"text": "Escitalopram , given in addition to mood stabilising medications , is significantly more efficacious , measured by response and remission rates than placebo in bipolar depression ( the acute phase study ) .", "label": "", "metadata": {}, "score": "61.65606"}
{"text": "The use of analgesics such as propoxyphene , codeine , acetaminophen plus codeine , or aspirin for pain relief was permitted .Patients were randomised 1:1:1:1 to receive weekly sc injections of adalimumab ( 20 , 40 , or 80 mg ) or placebo .", "label": "", "metadata": {}, "score": "61.658638"}
{"text": "End points .The primary efficacy variable was the number of gout flares per patient from day 1 through week 12 .Secondary end points , also assessed from day 1 through week 12 , included the proportion of patients with flares , the number of gout flare days per patient , and the number of days per patient with a pain score of ?", "label": "", "metadata": {}, "score": "61.677902"}
{"text": "Overall and pairwise comparison p - values are from analysis of variance without adjusting for covariates .Asian : from the 2 studies conducted in Asia ; Caucasian : from the 2 studies conducted outside Asia .", "label": "", "metadata": {}, "score": "61.753487"}
{"text": "The 12-week ACR50 was 17.4 % in the 20 mg twice daily arm , 13.4 % in the 40 mg once daily arm and 2.9 % in the placebo arm .", "label": "", "metadata": {}, "score": "61.800285"}
{"text": "Including a term for interaction between physiotherapy and treatment group in the same models did affect model fit but did not Table 3 . 326 ) Sham Acupuncture Group ( n ?", "label": "", "metadata": {}, "score": "61.91136"}
{"text": "Patients were required to provide written informed consent .After being screened for eligibility , patients discontinued all DMARDs four weeks before receiving the first injection of the study drug .", "label": "", "metadata": {}, "score": "61.95648"}
{"text": "A single dose placebo controlled phase I study of the fully human anti - TNF antibody D2E7 in patients with rheumatoid arthritis .Arthritis Rheum 1998 ; 41 : S57 ( abstr 148 ) .", "label": "", "metadata": {}, "score": "61.959713"}
{"text": "Construct validation of patient global impression of severity ( PGI - S ) and improvement ( PGI - I ) questionnaires in the treatment of men with lower urinary tract symptoms secondary to benign prostatic hyperplasia .", "label": "", "metadata": {}, "score": "61.99884"}
{"text": "Table 1 . 5 \" indicates 5 additional sessions or visits if treatment was graded as partially successful after 6 weeks .\u00a7 Rescue medication when acupuncture failed to prevent pain .", "label": "", "metadata": {}, "score": "62.0122"}
{"text": "One year efficacy results of the fully human anti - TNF antibody D2E7 in rheumatoid arthritis .Arthritis Rheum 2000 ; 43 : S269 ( abstr 1218 ) .", "label": "", "metadata": {}, "score": "62.10871"}
{"text": "[ PMID : 8628042 ] 15 .Angst F , Aeschlimann A , Stucki G. Smallest detectable and minimal clini- cally important differences of rehabilitation intervention with their implications for required sample sizes using WOMAC and SF-36 quality of life measurement instruments in patients with osteoarthritis of the lower extremities .", "label": "", "metadata": {}, "score": "62.147423"}
{"text": "Data demonstrated a clinically relevant and statistically significant improvement at week 12 in the signs and symptoms of psoriatic arthritis .The treatment was well tolerated and adverse events were consistent with those seen in other trials of certolizumab pegol .", "label": "", "metadata": {}, "score": "62.206783"}
{"text": "doses of the fully human anti - TNF - antibody D2E7 in patients with rheumatoid arthritis .Arthritis Rheum 1998 ; 41 : S55 ( abstr 137 ) .", "label": "", "metadata": {}, "score": "62.2124"}
{"text": "Last , there is not yet an established defini- tion of gout flare ( 23 ) .While the definition of flare used in our analyses is relevant for patients and has previously been used in studies of urate - lowering strategies , it may lack specificity ( 17 ) .", "label": "", "metadata": {}, "score": "62.214073"}
{"text": "Medication : Escitalopram 10 - 20 mg daily or placebo in addition to mood stabilisers .The dose of mood stabilisers must have been constant for the last six weeks prior to randomisation .", "label": "", "metadata": {}, "score": "62.331642"}
{"text": "Effective combination of the fully human anti - TNF antibody D2E7 and methotrexate in active rheumatoid arthritis .Ann Rheum Dis 1999 ; 58 ( suppl ) : 217 ( abstr 907 ) .", "label": "", "metadata": {}, "score": "62.44429"}
{"text": "The subjects were randomized to receive subcutaneous ( SC ) injections of placebo or golimumab ( 50 or 100 mg ) at weeks zero , four , eight , twelve , sixteen and twenty .", "label": "", "metadata": {}, "score": "62.51412"}
{"text": "No rebound in the flare rate was observed for 6 weeks after discontinuation of rilonacept or placebo at week 16 .The current findings indicate that rilonacept significantly reduces the frequency of gout flares during the initial period of treatment with urate - lowering therapy , with a favorable safety profile .", "label": "", "metadata": {}, "score": "62.55623"}
{"text": "The study met its primary endpoint , the American College of Rheumatology response criteria ( ACR 20 ) , at week 24 .Secukinumab was well - tolerated in the study , with a safety profile generally consistent with that observed in the psoriasis clinical trial program .", "label": "", "metadata": {}, "score": "62.572937"}
{"text": "In a sys- tematic review , 4 of 7 trials conducted in a total of 393 patients with knee osteoarthritis showed statistically signif- icant effects of acupuncture compared with conservative therapy alone or sham acupuncture ( 6 ) .", "label": "", "metadata": {}, "score": "62.58271"}
{"text": "Importantly , the similarity of the magnitude of the pain reduction observed with indomethacin in this study to that reported in previous studies [ 38,39 ] buttresses the current data .", "label": "", "metadata": {}, "score": "62.606537"}
{"text": "Data on this variable were missing in 16 patients .Of the 345 pa- tients who said they knew their treatment , 154 ( 45 % ) guessed incorrectly .", "label": "", "metadata": {}, "score": "62.626377"}
{"text": "Barry MJ , Fowler FJ Jr , O'Leary MP , Bruskewitz RC , Holtgrewe HL , Mebust WK , Cockett AT , The American Urological Association symptom index for benign prostatic hyperplasia .", "label": "", "metadata": {}, "score": "62.705143"}
{"text": "54.0 mg in the rilonacept group [ n ?41 ] ) .While allopurinol could be titrated once a month and physi- cians were reminded to titrate to target urate level , the target serum urate level of ?", "label": "", "metadata": {}, "score": "62.730667"}
{"text": "During this study , patients were carefully monitored for episodes of serious infection and immunological reactions .The incidence of serious infections in adalimumab treated patients ( 2 % ) was slightly less than the expected incidence of these events in patients with RA receiving immunosuppressant drugs ( 2.9 % ) .", "label": "", "metadata": {}, "score": "62.83402"}
{"text": "Findings suggest that , for some patients , transdermal buprenorphine may be effective in the treatment of chronic cancer pain .Limitations : .There was a substantial dropout rate after the two - week initial study .", "label": "", "metadata": {}, "score": "62.83538"}
{"text": "In addition , we attempted to identify a population in routine care who may be treated with not only methotrexate but other DMARD , with the subsequent addition of tocilizumab to improve outcomes given an inadequate response with previous therapy .", "label": "", "metadata": {}, "score": "62.83852"}
{"text": "To compare the efficacy and the risk of \" mood switching \" of escitalopram and placebo in the acute phase treatment of bipolar depression in patients already taking mood stabilising medication .", "label": "", "metadata": {}, "score": "62.849266"}
{"text": "Differing provisions from the publisher 's actual policy or licence agreement may be applicable .Also in a meta - analyses[26]also concluded that acupuncture was not better than controls in reducing the WOMAC score of knee OA .", "label": "", "metadata": {}, "score": "62.850494"}
{"text": "Sarawate CA , Brewer KK , Yang W , Patel PA , Schumacher HR , Saag KG , et al .Gout medication treatment patterns and adher- ence to standards of care from a managed care perspective .", "label": "", "metadata": {}, "score": "62.92237"}
{"text": "Dr. Terkeltaub has received consulting fees , speak- ing fees , and/or honoraria from Regeneron , Novartis , and URL Pharma ( less than $ 10,000 each ) and has served as a paid consultant to the investment analysts Guidepoint Global and the Coleman Group .", "label": "", "metadata": {}, "score": "62.982563"}
{"text": "Responders are re - randomised to 32 weeks of maintenance treatment ( phase 2 ) .Phase 2 has nine clinical assessments .Patients who develop hypomania , mania or depressive episodes ( defined as episodes meeting DSM - IV criteria for Major Depressive Episode with MADRS scores of at least 20 points ) leave the study in this phase .", "label": "", "metadata": {}, "score": "63.033592"}
{"text": "Primary End Point The observed success rates were 53.1 % for the TCA group , 51.0 % for the sham acupuncture group , and 29.1 % for the conservative therapy group ( Table 3 ) .", "label": "", "metadata": {}, "score": "63.033966"}
{"text": "The urinary symptoms can be categorized into voiding , storage and post - micturition symptoms .Item scores are summed for a total IPSS score that ranges from 0 to 35 with a higher score indicating more severe symptoms .", "label": "", "metadata": {}, "score": "63.144867"}
{"text": "The urinary symptoms can be categorized into voiding , storage and post - micturition symptoms .Item scores are summed for a total IPSS score that ranges from 0 to 35 with a higher score indicating more severe symptoms .", "label": "", "metadata": {}, "score": "63.144867"}
{"text": "The PGI - I asks the patient to best describe how his urinary symptoms are now , compared with how they were before he began taking medication in the study .", "label": "", "metadata": {}, "score": "63.160675"}
{"text": "The PGI - I asks the patient to best describe how his urinary symptoms are now , compared with how they were before he began taking medication in the study .", "label": "", "metadata": {}, "score": "63.160675"}
{"text": "When Qmax was evaluated in the recently updated AUA BPH treatment guidelines 2010 , the AUA panel concluded that Qmax correlates poorly with subjective symptoms , PVR and prostate size , and is a weak , patient - oriented outcome in that the patient only marginally experiences flow rate differences .", "label": "", "metadata": {}, "score": "63.2943"}
{"text": "When Qmax was evaluated in the recently updated AUA BPH treatment guidelines 2010 , the AUA panel concluded that Qmax correlates poorly with subjective symptoms , PVR and prostate size , and is a weak , patient - oriented outcome in that the patient only marginally experiences flow rate differences .", "label": "", "metadata": {}, "score": "63.2943"}
{"text": "Statistical analysis .The intent - to - treat ( ITT ) population consisted of all randomly assigned patients who received at least one administration of study medication .", "label": "", "metadata": {}, "score": "63.309002"}
{"text": "PubMed View Article .Angalakuditi M , Seifert RF , Hayes RP , O'Leary MP , Viktrup L : Measurement properties of the benign prostatic hyperplasia impact index in tadalafil studies .", "label": "", "metadata": {}, "score": "63.334236"}
{"text": "These daily reports , which included assessment of pain and global well - being ( 0 - 10 numerical rating scale , recall period 24 hours for both measures ) , also enabled determination of when a flare ended ( i.e. , when pain returned to baseline ) and estimation of flare duration .", "label": "", "metadata": {}, "score": "63.454678"}
{"text": "Additionally , ACR responses with adalimumab were achieved more rapidly than with placebo , with 82/115 ( 71 % ) of the ultimate ACR20 response rate to adalimumab treatment achieved at week 2 .", "label": "", "metadata": {}, "score": "63.456535"}
{"text": "Results .Participant characteristics .A total of 35.6 % had severe symptoms of BPH - LUTS per IPSS and 48.6 % had severe outlet obstruction per urinary peak flow rate ( Qmax ) ( Table 1 ) .", "label": "", "metadata": {}, "score": "63.60374"}
{"text": "Fibromyalgia syndrome composite responders needed to satisfy the pain composite criteria as well as demonstrate at least a 6-point improvement in their SF-36 physical component summary ( SF-36 PCS ) score .", "label": "", "metadata": {}, "score": "63.61493"}
{"text": "Posi- tive results of a phase II study comparing canakinumab , a monoclonal antibody specific for IL-1 ? , to the active comparator colchicine 0.5 mg daily for gout flare pro- phylaxis in patients initiating urate - lowering therapy were reported recently ( 17 ) .", "label": "", "metadata": {}, "score": "63.625748"}
{"text": "A dose escalation study designed to demonstrate the safety , tolerability and efficacy of the fully human anti - TNF antibody , D2E7 , given in combination with methotrexate ( MTX ) in patients with active RA .", "label": "", "metadata": {}, "score": "63.63277"}
{"text": "Construct validity of the PGI - I .Similar trends of correlations were observed across ethnicity , race and V2 severity ( Table 5 ) .", "label": "", "metadata": {}, "score": "63.720093"}
{"text": "Construct validity of the PGI - I .Similar trends of correlations were observed across ethnicity , race and V2 severity ( Table 5 ) .", "label": "", "metadata": {}, "score": "63.720093"}
{"text": "Arthritis Rheum 2006;54:383 - 6 .Riedel AA , Nelson M , Joseph - Ridge N , Wallace K , MacDonald P , Becker M. Compliance with allopurinol therapy among managed care enrollees with gout : a retrospective analysis of administrative claims .", "label": "", "metadata": {}, "score": "63.72073"}
{"text": "The results of the 40 week and 52 week continuation studies will be presented separately .Those who participated beyond week 12 were given open label adalimumab .", "label": "", "metadata": {}, "score": "63.761803"}
{"text": "Construct validity of the PGI - S .Similar trends of correlations were observed across ethnicity , race and baseline severity ( Table 3 ) .", "label": "", "metadata": {}, "score": "63.780197"}
{"text": "Construct validity of the PGI - S .Similar trends of correlations were observed across ethnicity , race and baseline severity ( Table 3 ) .", "label": "", "metadata": {}, "score": "63.780197"}
{"text": "Two hundred and thirty three patients completed the study-186 ( 87 % ) patients in the adalimumab groups and 47 ( 67 % ) in the placebo group .", "label": "", "metadata": {}, "score": "63.826233"}
{"text": "Moreland LW , Schiff MH , Baumgartner SW , Tindall EA , Fleischmann RM , Bulpitt KJ , et al .Etanercept therapy in rheumatoid arthritis : a randomized , controlled trial .", "label": "", "metadata": {}, "score": "63.8537"}
{"text": "Assuming an ACR20 response rate of 20 % , 90 % power , and a drop out rate of 10 % , a sample size of 64 patients in each treatment arm was required .", "label": "", "metadata": {}, "score": "63.86436"}
{"text": "A total of 1692 men completed the PGI - S at V2 ( before the placebo run - in period ) and 1628 men completed the PGI - I at last visit .", "label": "", "metadata": {}, "score": "63.970345"}
{"text": "From the adalimumab 20 mg group , 2 ( 3 % ) patients were withdrawn because of lack of efficacy and 1 ( 1 % ) patient because of protocol deviation and withdrawal of consent .", "label": "", "metadata": {}, "score": "63.99547"}
{"text": "DISCUSSION Class- or drug - specific limitations of colchicine and NSAIDs , agents that are currently recommended for gout flare prophylaxis , indicate a need for alterna- tives in some patients .", "label": "", "metadata": {}, "score": "64.04881"}
{"text": "Conclusions : Adalimumab given as monotreatment to patients with longstanding , severe RA refractory to traditional DMARDs produced a rapid , sustained response and was safe and well tolerated , with no dose limiting side effects .", "label": "", "metadata": {}, "score": "64.098946"}
{"text": "The mean times to the onset of ACR responses were dose dependent , with the adalimumab 20 and 40 mg groups having similar mean times to the onset of ACR20 response and the 80 mg group having a somewhat shorter time .", "label": "", "metadata": {}, "score": "64.102776"}
{"text": "In addition , this study employed as a primary endpoint the highest threshold of the clinically relevant outcome ( American College of Rheumatology ( ACR ) 50 % improvement ; ACR50 ) .", "label": "", "metadata": {}, "score": "64.11207"}
{"text": "365 ) Conservative Therapy Group ( n ?Two of the patients in the conservative treatment group had received previous intravenous medication .Page 6 . wise comparisons showed statistically significantly in- creased success rates in the TCA and sham acupuncture groups compared with the conservative therapy group ( P ? 0.001 for both comparisons ) and no difference be- tween the TCA and sham acupuncture groups ( P ? 5.4 % to 9.6 % ) for TCA versus sham acu- puncture .", "label": "", "metadata": {}, "score": "64.611916"}
{"text": "Interventions Conservative therapy involved 10 visits to practitioners with consultation and a prescription for diclofenac , up to 150 mg / d , or rofecoxib , 25 mg / d , as needed until week 23 .", "label": "", "metadata": {}, "score": "64.8358"}
{"text": "For Use as an Intervention For Chronic Pain .Author and Year .Poulain , P. , Denier , W. , Douma , J. , Hoerauf , K. , Samija , M. , Sopata , M. , & Wolfram , G. ( 2008 ) .", "label": "", "metadata": {}, "score": "64.88029"}
{"text": "Serum samples were analysed for anti - adalimumab antibodies using a validated double antigen , enzyme linked immunosorbent assay ( ELISA ) .ANAs were measured at study entry , baseline , and monthly thereafter , and anti - adalimumab antibodies were measured at all scheduled study visits .", "label": "", "metadata": {}, "score": "64.94219"}
{"text": "Based on positive phase III results , Cypress and Forest planned to file an NDA around the end of 2007 .Schering Plough and Centocor reported positive results from a phase III trial of golimumab for the treatment of psoriatic arthritis .", "label": "", "metadata": {}, "score": "64.95629"}
{"text": "Sarawate CA , Patel PA , Schumacher HR , Yang W , Brewer KK , Bakst AW .Serum urate levels and gout flares : analysis from managed care data .", "label": "", "metadata": {}, "score": "64.95812"}
{"text": "Time to flare was calculated based on Kaplan - Meier estima- tion .Mean ?SD values are reported .Because pain scores were not always reported on all days during which gout flare occurred , sensitivity analyses using 3 different imputation methods ( as prespecified in the statistical analysis plan ) were performed for the secondary outcome of mean number of days per patient with pain score ?", "label": "", "metadata": {}, "score": "64.97787"}
{"text": "Supported by Regeneron Pharmaceuticals , Inc. 1H. Dr. Schumacher has received consulting fees , speaking fees , and/or honoraria from Regeneron , Takeda , Savient , Ardea , Pfizer , Xoma , and Novartis ( less than $ 10,000 each ) .", "label": "", "metadata": {}, "score": "64.989365"}
{"text": "Patient consent Obtained .Provenance and peer review Not commissioned ; externally peer reviewed .The good initial response to therapy with a combination of traditional disease - modifying antirheumatic drugs is sustained over time : the eleven - year results of the Finnish rheumatoid arthritis combination therapy trial .", "label": "", "metadata": {}, "score": "65.02818"}
{"text": "Another factor that may affect the magnitude of the correlation is that the urinary symptoms that the participants are asked to consider are not completely identical for each questionnaire .", "label": "", "metadata": {}, "score": "65.04596"}
{"text": "Another factor that may affect the magnitude of the correlation is that the urinary symptoms that the participants are asked to consider are not completely identical for each questionnaire .", "label": "", "metadata": {}, "score": "65.04596"}
{"text": "Shoji A , Yamanaka H , Kamatani N. A retrospective study of the relationship between serum urate level and recurrent attacks of gouty arthritis : evidence for reduction of recurrent gouty arthritis with antihyperuricemic therapy .", "label": "", "metadata": {}, "score": "65.14425"}
{"text": "Four patients developed anti - adalimumab antibodies during the study .Because adalimumab has sequences that are germline human in the framework regions , it is expected to have reduced immunogenicity compared with antibodies that contain sequences derived from non - human species .", "label": "", "metadata": {}, "score": "65.17764"}
{"text": "If a patient fulfilled the criterion for additional visits , the interviewer informed the patient during the in- terview and informed the related investigator by fax .", "label": "", "metadata": {}, "score": "65.206375"}
{"text": "UCB issued results from a phase III trial of certolizumab pegol for psoriatic arthritis .This global , 48 week , double - blind , parallel - group trial , RAPID - PsA , enrolled 409 subjects with adult onset active psoriatic arthritis .", "label": "", "metadata": {}, "score": "65.23264"}
{"text": "Apart from hematomas , no obvious adverse effects due to acupuncture were de- tected .This supports known statements about the safety of acupuncture ( 29 ) .", "label": "", "metadata": {}, "score": "65.30456"}
{"text": "The primary endpoint was at least a 20 percent improvement in arthritis signs and symptoms ( ACR 20 ) response at week fourteen for combined golimumab groups and individual golimumab dose groups versus placebo .", "label": "", "metadata": {}, "score": "65.34898"}
{"text": "Study visits occurred every 4 weeks during the treat- ment period , with a 6-week posttreatment followup visit .Assessments included physical examination , determination of serum urate levels and other laboratory assessments , and review of flare diary and reported adverse events .", "label": "", "metadata": {}, "score": "65.37372"}
{"text": "Celgene released positive results from a phase II trial of apremilast for the treatment of psoriatic arthritis .This multi - center , randomized , double - blind , placebo - controlled , three - arm study enrolled 204 subjects who received apremilast 20 mg twice per day , apremilast 40 mg once per day or placebo for 12 weeks .", "label": "", "metadata": {}, "score": "65.45142"}
{"text": "Appendix Table 4 . 1 means success rate below 0.5 ; an odds ratio ? 1 favors the first group .Odds ratios are provided to show how parameter estimates were affected by the incorporation of additional model terms .", "label": "", "metadata": {}, "score": "65.48251"}
{"text": "56.6 mg in the placebo group [ n ?41 ] and 326.5 ? 43.1 mg in the rilonacept group [ n ?41 ] ) and 16 weeks ( observed data 332.1 ? 65.7 mg in the placebo group [ n ?", "label": "", "metadata": {}, "score": "65.537636"}
{"text": "The protocol prescribed the same general proce- dure , diagnostics , and communication with patients in the TCA and sham acupuncture groups .The same types of acupuncture needles were used for TCA and sham acupuncture , and all investigators were trained in both techniques .", "label": "", "metadata": {}, "score": "65.62976"}
{"text": "ACR core criteria .Patients experienced an immediate , rapid decline in mean TJC after the initial injection of adalimumab .At week 2 , mean reductions of 7.7 , 9.5 , and 11.4 were reported for the adalimumab 20 , 40 , and 80 mg groups , respectively ; the placebo group showed little improvement ( that is , a mean decrease of 1.0 ) .", "label": "", "metadata": {}, "score": "65.64782"}
{"text": "Diagnostic criteria for Mania and Hypomania at week 1 , 2 , 4 , 6 , 8 , 9 , 10 , 12 , 16 , 20 , 24 , 28 , 34 and 40 .", "label": "", "metadata": {}, "score": "65.666565"}
{"text": "SD 97.9 ?5.4 % of doses versus 92.4 % ?14.5 % ; P ? 0.026 by Student 's t - test ) and week 16 ( 97.3 ? 4.7 % versus 91.3 % ?", "label": "", "metadata": {}, "score": "65.71094"}
{"text": "The patient must score at least 15 points on the MADRS and have a CGI - S score of 3 or more during this episode .", "label": "", "metadata": {}, "score": "65.718285"}
{"text": "A long - term study .Acta Anaesthesiol Scand .[ PMID :1514335 ] 19 .Molsberger A , Bo \u00a8wing G , Jensen K , Lorek M. Acupuncture treatment for the relief of gonarthrosis pain - a controlled clinical trial .", "label": "", "metadata": {}, "score": "65.76541"}
{"text": "The probability of adverse events increases with the dura- tion of pharmacologic treatment .At the 1997 National Institutes of Health Consensus Conference on acupuncture ( 5 ) , acupuncture was proposed as an option for reducing the dose of or avoiding the use of medication .", "label": "", "metadata": {}, "score": "65.79074"}
{"text": "PubMed View Article .Kingery L , Martin ML , Naegeli AN , Khan S , Viktrup L : Content validity of the Benign Prostatic Hyperplasia Impact Index ( BII ) ; a measure of how urinary trouble and problems associated with BPH may impact the patient .", "label": "", "metadata": {}, "score": "65.806206"}
{"text": "In most measures of efficacy at week 12 , adalimumab 40 mg was associated with better results than the other doses .Figure 3 illustrates the improvements in ACR criteria attained by this group over the entire treatment period .", "label": "", "metadata": {}, "score": "65.80662"}
{"text": "Authors provide no information about the value of transdermal buprenorphine compared to the value of other analgesics .Despite the popularity of acupuncture , evidence of its efficacy for reducing pain remains equivocal .", "label": "", "metadata": {}, "score": "65.81198"}
{"text": "SD 5.9 ? 1.4 mg / dl in the placebo group [ n ? 32 ] and 5.5 ? 1.4 mg / dl in the rilonacept group [ n ? 38 ] ) and week 16 ( 6.0 ? 1.2 mg / dl in the placebo group [ n ? 31 ] and 5.9 ? 1.4 mg / dl in the rilonacept group [ n ? 37 ] ) .", "label": "", "metadata": {}, "score": "65.84431"}
{"text": "Because of the small number of cases , no overall conclusions can be drawn about the overall efficacy and safety of patients who develop anti - adalimumab antibodies .", "label": "", "metadata": {}, "score": "65.859795"}
{"text": "Long - term follow - up results of the Keitel function test .Brief definite report .Z Rheumatol 2001 ; 60 : 69 -73 .", "label": "", "metadata": {}, "score": "65.96077"}
{"text": "Streitberger K , Kleinhenz J. Introducing a placebo needle into acupuncture research .Lancet .[ PMID :9717924 ] 21 .Altman R , Asch E , Bloch D , Bole G , Borenstein D , Brandt K , et al .", "label": "", "metadata": {}, "score": "65.995865"}
{"text": "In summary , this well - controlled study provides evidence supporting the notion that IL-1 inhibition has a role in the prevention of flares of acute gout .", "label": "", "metadata": {}, "score": "66.04637"}
{"text": "Efficacy of the fully human anti - TNF antibody D2E7 in rheumatoid arthritis .Arthritis Rheum 1999 ; 42 : S400 ( abstr 1977 ) .", "label": "", "metadata": {}, "score": "66.140335"}
{"text": "The second type of analysis , unadjusted one - way analysis of variance ( ANOVA ) , was performed to evaluate the differences of these measures among the 4 PGI - S categories and pair - wise comparisons were made .", "label": "", "metadata": {}, "score": "66.186386"}
{"text": "The second type of analysis , unadjusted one - way analysis of variance ( ANOVA ) , was performed to evaluate the differences of these measures among the 4 PGI - S categories and pair - wise comparisons were made .", "label": "", "metadata": {}, "score": "66.186386"}
{"text": "Radiographic assessment of disease progression in rheumatoid arthritis patients enrolled in the cooperative systematic studies of the rheumatic diseases program randomized clinical trial of methotrexate , auranofin , or a combination of the two .", "label": "", "metadata": {}, "score": "66.23155"}
{"text": "Felson DT , Anderson JJ , Boers M , Bombardier C , Chernoff M , Fried B , et al .The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials .", "label": "", "metadata": {}, "score": "66.23425"}
{"text": "PATIENTS AND METHODS Study design and patient population .This phase II randomized , double - blind , placebo - controlled trial was per- formed at 27 study centers in the US .", "label": "", "metadata": {}, "score": "66.26354"}
{"text": "Time course of American College of Rheumatology responses .( A ) ACR20 response ; ( B ) ACR50 response ; ( C ) ACR70 response .", "label": "", "metadata": {}, "score": "66.37286"}
{"text": "At the 12 week assessment , more than 50 % of patients in each adalimumab group were ACR20 responders and about 20 % had attained an ACR50 response .", "label": "", "metadata": {}, "score": "66.43356"}
{"text": "Two ( 3 % ) patients receiving adalimumab 80 mg developed serious infections , one a urinary tract infection and the other a bacterial infection with fever .", "label": "", "metadata": {}, "score": "66.4462"}
{"text": "The risk of infections with biologic therapies for rheumatoid arthritis .Semin Arthritis Rheum 2010;39:327 - 46 .Schlesinger N. Management of acute and chronic gouty arthritis : present state - of - the - art .", "label": "", "metadata": {}, "score": "66.45709"}
{"text": "Elliott MJ , Maini RN , Feldmann M , Long - Fox A , Charles P , Katsikis P , et al .Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumour necrosis factor \u03b1 .", "label": "", "metadata": {}, "score": "66.693924"}
{"text": "Hoskison KT , Wortmann RL .Management of gout in older adults : barriers to optimal control .Drugs Aging 2007;24:21 - 36 .Martinon F , Petrilli V , Mayor A , Tardivel A , Tschopp J. Gout- associated uric acid crystals activate the NALP3 inflammasome .", "label": "", "metadata": {}, "score": "66.6947"}
{"text": "The study popu- lation was predominantly non - Hispanic white and male , with a mean age of 51.0 years .On average , the baseline serum uric acid level was 9.1 mg / dl , the time from gout diagnosis was 9.7 years , and the number of flares re- ported for the previous year was 4.5 .", "label": "", "metadata": {}, "score": "66.809105"}
{"text": "The PGI - S was administered once at the beginning of the placebo lead - in period ( V2 ) .All patient - reported measures were originally developed in English for the United States .", "label": "", "metadata": {}, "score": "66.82606"}
{"text": "The PGI - S was administered once at the beginning of the placebo lead - in period ( V2 ) .All patient - reported measures were originally developed in English for the United States .", "label": "", "metadata": {}, "score": "66.82606"}
{"text": "Keywords .Patient global impression scale Lower urinary tract symptoms Construct validity .Electronic supplementary material .The online version of this article ( doi : 10 .", "label": "", "metadata": {}, "score": "66.85474"}
{"text": "Assessments .The following assessments will be carried out : : .MADRS , GAF , IDS - RS , and CGI - I at week 1 , 2 , 4 , 6 , 8 , 9 , 10 , 12 , 16 , 20 , 24 , 28 , 34 and 40 .", "label": "", "metadata": {}, "score": "66.87926"}
{"text": "Borstad GC , Bryant LR , Abel MP , Scroggie DA , Harris MD , Alloway JA .Colchicine for prophylaxis of acute flares when initiating allopurinol for chronic gouty arthritis .", "label": "", "metadata": {}, "score": "66.92806"}
{"text": "Puhl W , Bernau A , Bo \u00a8hle E , Brune K , Gerhardt P , Greitemann B , et al .[Ambulatory diagnosis and therapy of gonarthrosis].", "label": "", "metadata": {}, "score": "66.97017"}
{"text": "Use of adjuvant analgesics - such as tricyclic antidepressants , benzodiazepines , anticonvulsants , muscle relaxants , or corticosteroids - was allowed if doses were stable .", "label": "", "metadata": {}, "score": "67.06822"}
{"text": "42 ) Rilonacept group ( n ? 15 % of patients)\u00a7 Infections and infestations Musculoskeletal and connective tissue disorders By high - level term ( in ?", "label": "", "metadata": {}, "score": "67.2183"}
{"text": "It is interesting to note that across different lower urinary tract conditions , objective parameters do not seem to sufficiently capture patient - reported symptoms .", "label": "", "metadata": {}, "score": "67.28023"}
{"text": "It is interesting to note that across different lower urinary tract conditions , objective parameters do not seem to sufficiently capture patient - reported symptoms .", "label": "", "metadata": {}, "score": "67.28023"}
{"text": "Asian : from the 2 studies conducted in Asia ; Caucasian : from the 2 studies conducted outside Asia .Abstract .Objectives : To evaluate efficacy , dose response , safety , and tolerability of adalimumab ( D2E7 ) in disease modifying antirheumatic drug ( DMARD ) refractory patients with longstanding , active rheumatoid arthritis ( RA ) .", "label": "", "metadata": {}, "score": "67.31003"}
{"text": "No systemic allergic reactions were reported with adalimumab treatment , enabling long term administration without the concurrent use of immunosuppressant drugs such as MTX .Patients completing this 12 week placebo controlled study were subsequently entered into a 40 week blinded continuation study of adalimumab , followed by an open label study for an additional year in order to validate the chronic efficacy and safety of adalimumab .", "label": "", "metadata": {}, "score": "67.33957"}
{"text": "Responders to escitalopram are re - randomised to escitalopram or placebo for the continuation phase while placebo responders continue taking placebo for the continuation phase .", "label": "", "metadata": {}, "score": "67.344086"}
{"text": "Abstract / OtherAbstract : .BACKGROUND : Lower urinary tract symptoms ( LUTS ) in aging men are often associated with benign prostatic hyperplasia ( BPH ) .", "label": "", "metadata": {}, "score": "67.455185"}
{"text": "Transdermal buprenorphine may be helpful to some patients , but in this study more than one - third of cases did not respond to the treatment .", "label": "", "metadata": {}, "score": "67.48867"}
{"text": "A total of 35.6 % had severe symptoms of BPH - LUTS per IPSS and 48.6 % had severe outlet obstruction per urinary peak flow rate ( Qmax ) ( Table 1 ) .", "label": "", "metadata": {}, "score": "67.49803"}
{"text": "Objective To evaluate efficacy of tocilizumab in US patients with moderate to severe active rheumatoid arthritis ( RA ) and inadequate clinical response to disease - modifying antirheumatic drugs ( DMARD ) .", "label": "", "metadata": {}, "score": "67.761536"}
{"text": "All authors read and approved the final manuscript .tb00138.x9179665 .Abrams P , Cardozo L , Fall M , Griffiths D , Rosier P , Ulmsten U , van Kerrebroeck P , Victor A , Wein A , Standardisation Sub - committee of the International Continence Society .", "label": "", "metadata": {}, "score": "67.780075"}
{"text": "Mean RAPID3 score over time .DMARD , disease - modifying antirheumatic drug ; RAPID3 , routine assessment of patient index data ; TCZ , tocilizumab .", "label": "", "metadata": {}, "score": "67.79102"}
{"text": "Treatment - induced changes in the WOMAC score and its subscales between the treatment groups at specific time points were studied by using a linear mixed- effects model in which treatment and number of affected knees were considered as fixed and regional cluster was considered as a random effect .", "label": "", "metadata": {}, "score": "67.79723"}
{"text": "The mean times to the onset of ACR20 and ACR50 responses were consistently shorter for all adalimumab doses than for placebo .The rapid clinical response to adalimumab treatment also was shown by the early ( that is , week 2 ) statistically significant decline in the number of swollen and tender joints as well as improvements in other ACR core criteria compared with placebo in the DMARD refractory population .", "label": "", "metadata": {}, "score": "67.83257"}
{"text": "24- 27 Both agents are indicated for the treatment of moderate to severe DMARD refractory RA .28 , 29 Etanercept is administered subcutaneously ( sc ) , whereas infliximab is given intravenously and only in combination with MTX .", "label": "", "metadata": {}, "score": "67.85327"}
{"text": "A complete physical examination was performed at study entry ( screening ) , baseline , every two weeks , and , for those patients who withdrew , up to six months of follow up after the last study dose .", "label": "", "metadata": {}, "score": "67.878235"}
{"text": "Setting : 315 primary care practices staffed by 320 practitioners with at least 2 years ' experience in acupuncture .Patients : 1007 patients who had had chronic pain for at least 6 months due to osteoarthritis of the knee ( American College of Rheumatology [ ACR ] criteria and Kellgren - Lawrence score of 2 or 3 ) .", "label": "", "metadata": {}, "score": "67.895294"}
{"text": "steroidal anti - inflammatory drugs , including cyclooxygen- ase-2 inhibitors and nonopioid analgesics .Treatment is usually combined with patient education , social support , and physiotherapy .", "label": "", "metadata": {}, "score": "67.907455"}
{"text": "May 13 , 2013 .Celgene International reported results from a phase III trial of apremilast for the treatment of psoriatic arthritis .This multi - center , double - blind , placebo - controlled , parallel - group study enrolled over 500 patients with psoriatic arthritis .", "label": "", "metadata": {}, "score": "67.92757"}
{"text": "Study 2 ( LVHR ) was a randomized , double - blind , 3-group , placebo - controlled , parallel - design , multinational study to evaluate the efficacy and safety of tadalafil 2.5- and 5-mg once - daily dosing for 12 weeks for the treatment of erectile dysfunction ( ED ) and BPH - LUTS .", "label": "", "metadata": {}, "score": "67.931625"}
{"text": "The effects of drug therapy on radiographic progression of rheumatoid arthritis .Results of a 36-week randomized trial comparing methotrexate and auranofin .Arthritis Rheum 1993 ; 36 : 613 -19 .", "label": "", "metadata": {}, "score": "67.97602"}
{"text": "Sample Characteristics : .Initially , 289 patients entered the trial .The analyzed sample was composed of 188 patients .Mean patient age was 63 years .", "label": "", "metadata": {}, "score": "68.008965"}
{"text": "Barrera P , Joosten LAB , den Broeder AA , van de Putte LBA , van Riel PLCM , van den Berg WB .Effects of treatment with a fully human anti - tumour necrosis factor \u03b1 monoclonal antibody on the local and systemic homeostasis of interleukin 1 and TNF\u03b1 in patients with rheumatoid arthritis .", "label": "", "metadata": {}, "score": "68.01439"}
{"text": "Randomized , controlled trial .315 primary care practices staffed by 320 practitioners with at least 2 years ' experience in acupuncture .1007 patients who had had chronic pain for at least 6 months due to osteoarthritis of the knee ( American College of Rheumatology [ ACR ] criteria and Kellgren - Lawrence score of 2 or 3 ) .", "label": "", "metadata": {}, "score": "68.07315"}
{"text": "Bathon JM , Martin RW , Fleischmann RM , Tesser JR , Schiff MH , Keystone EC , et al .A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis .", "label": "", "metadata": {}, "score": "68.08261"}
{"text": "BMC Complement Altern Med .[ PMID :15040805 ] 14 .Ware J Jr , Kosinski M , Keller SD .A 12-Item Short - Form Health Survey : construction of scales and preliminary tests of reliability and validity .", "label": "", "metadata": {}, "score": "68.183105"}
{"text": "Appendix Table 6-Continued Preferred Term ( MedDRA)Traditional Chinese Acupuncture Group ( n ? 326 ) , n ( % )Sham Acupuncture Group ( n ? 265 ) , n ( % ) Conservative Therapy Group ( n ? 316 ) , n ( % ) Total ( n ?", "label": "", "metadata": {}, "score": "68.20476"}
{"text": "Appendix Table 6-Continued Preferred Term ( MedDRA)Traditional Chinese Acupuncture Group ( n ? 326 ) , n ( % )Sham Acupuncture Group ( n ? 265 ) , n ( % ) Conservative Therapy Group ( n ? 316 ) , n ( % ) Total ( n ?", "label": "", "metadata": {}, "score": "68.20476"}
{"text": "Most patients were women ( 79 % ) , and the majority were white ( 99 % ) .The mean duration of RA was 10.0 years , and baseline TJC and SJC averaged 31.5 and 19.5 , respectively .", "label": "", "metadata": {}, "score": "68.21637"}
{"text": "The allopurinol dosage was titrated monthly during the study in 100-mg increments , up to 800 mg / day , to attain a serum urate level of ?", "label": "", "metadata": {}, "score": "68.22716"}
{"text": "Background .Lower urinary tract symptoms ( LUTS ) in aging men are often associated with benign prostatic hyperplasia ( BPH ) .While regulatory evaluations of treatment benefit require an assessment of specific symptoms , a simpler approach to measuring patients ' perceptions of severity and symptom change may be particularly useful for clinical practice .", "label": "", "metadata": {}, "score": "68.28963"}
{"text": "Regarding urate - lowering therapies , the recombinant uricases pegloticase and rasburicase clearly showed their effectiveness in gout patients .Also in this case , new compounds are under development .", "label": "", "metadata": {}, "score": "68.367805"}
{"text": "Patients with other diseases affecting the knee , neurologic and psychiatric diseases , severe coagulopathy , pregnancy , or previous acupuncture treatment for osteoarthritis of the knee were excluded .", "label": "", "metadata": {}, "score": "68.52152"}
{"text": "Changes in Qmax included in this validation were based on assessment at V2 and at endpoint .Patient - reported measures .The change in IPSS from randomization ( V3 ) to endpoint was the primary objective in all the studies ; changes in IPSS - QoL , BII and Qmax from V3 to endpoint were secondary objectives .", "label": "", "metadata": {}, "score": "68.5233"}
{"text": "Changes in Qmax included in this validation were based on assessment at V2 and at endpoint .Patient - reported measures .The change in IPSS from randomization ( V3 ) to endpoint was the primary objective in all the studies ; changes in IPSS - QoL , BII and Qmax from V3 to endpoint were secondary objectives .", "label": "", "metadata": {}, "score": "68.5233"}
{"text": "Remission : MADRS score of 12 or less at the end of the acute phase if the patient has completed at least four weeks of the study .", "label": "", "metadata": {}, "score": "68.538826"}
{"text": "Ann Rheum Dis 2009;68:1602 - 8 .McGonagle D , Tan AL , Shankaranarayana S , Madden J , Emery P , McDermott MF .Management of treatment resistant inflamma- tion of acute on chronic tophaceous gout with anakinra [ letter].", "label": "", "metadata": {}, "score": "68.59207"}
{"text": "Data demonstrated statistical significance was achieved for the primary endpoint of ACR 20 at week 16 for patients receiving apremilast 20 mg and 30 mg .", "label": "", "metadata": {}, "score": "68.60974"}
{"text": "The current findings indicate that rilonacept significantly reduces the frequency of gout flares during the initial period of treatment with urate- lowering therapy , with a favorable safety profile .", "label": "", "metadata": {}, "score": "68.66034"}
{"text": "The first 3 questions are scored from 0 to 3 , while the fourth is scored from 0 to 4 .Item scores are summed for a BII total score that ranges from 0 to 13 , with higher scores indicating more bother or problems associated with urinary symptoms within the previous month .", "label": "", "metadata": {}, "score": "68.66824"}
{"text": "The first 3 questions are scored from 0 to 3 , while the fourth is scored from 0 to 4 .Item scores are summed for a BII total score that ranges from 0 to 13 , with higher scores indicating more bother or problems associated with urinary symptoms within the previous month .", "label": "", "metadata": {}, "score": "68.66824"}
{"text": "Gout flares were treated at the investigator 's discretion for up to 10 days with NSAIDs or oral glucocorticoids .Flares were self - reported and assessed using a daily diary that was recorded via a telephone - based Interactive Voice Response System starting on day 1 of a flare until resolution of all symptoms .", "label": "", "metadata": {}, "score": "68.74125"}
{"text": "Among the IL-1\u03b2 inhibitors , the majority of studies involve drugs such as anakinra , canakinumab , and rilonacept , but other compounds are under development .", "label": "", "metadata": {}, "score": "68.76935"}
{"text": "Severity and relationship of adverse events to study drug were deter- mined by the investigator .Statistical analysis .All analyses were performed on the full analysis set using SAS version 9 ( SAS Institute ) .", "label": "", "metadata": {}, "score": "68.82251"}
{"text": "Modellvorhaben zur Beurteilung der Wirk- samkeit .Deutsches A\u00a8rzteblatt .Stucki G , Stoll T , Bru \u00a8hlmann P , Michel BA .Construct validation of the ACR 1991 revised criteria for global functional status in rheumatoid arthritis .", "label": "", "metadata": {}, "score": "68.98146"}
{"text": "Patients could request up to 5 additional sessions or visits if the initial treatment was viewed as being partially successful .Measurements : Success rate , as defined by at least 36 % improve- ment in Western Ontario and McMaster Universities Osteoarthritis Index ( WOMAC ) score at 26 weeks .", "label": "", "metadata": {}, "score": "68.98425"}
{"text": "Pharmacotherapeutic combination strategies with disease - modifying antirheumatic drugs in established rheumatoid arthritis .Baillieres Best Pract Res Clin Rheumatol 1999 ; 13 : 689 -700 .", "label": "", "metadata": {}, "score": "69.006134"}
{"text": "Pain reduction over the 72-hour period with rilonacept alone ( -0.69 \u00b1 0.97 ) was less than that in the other groups , but pain reduction was similar among groups at 72 hours .", "label": "", "metadata": {}, "score": "69.29517"}
{"text": "PubMed View Article .Arnold LM , Clauw D , Wang F , Ahl J , Gaynor PJ , Wohlreich MM : Flexible dosed duloxetine in the treatment of fibromyalgia : a randomized , double - blind , placebo - controlled trial .", "label": "", "metadata": {}, "score": "69.41925"}
{"text": "Table 1 . 42 ) Rilonacept group ( n ?41 )All patients ( n ? 83 )Age , years Male , no .", "label": "", "metadata": {}, "score": "69.535355"}
{"text": "DISCUSSION This study shows that both TCA and sham acupunc- ture improve pain and functionality in patients with osteo- arthritis of the knee more than conservative therapy .", "label": "", "metadata": {}, "score": "69.70842"}
{"text": "More than half of the progress in disease activity as reflected in the ACR core criteria occurred within two weeks of the initial dose of adalimumab .", "label": "", "metadata": {}, "score": "69.7108"}
{"text": "In conclusion , these data suggest tocilizumab , an anti - IL-6R monoclonal antibody , has early and sustained efficacy in patients with RA who have failed to respond adequately to previous DMARD therapy .", "label": "", "metadata": {}, "score": "69.76163"}
{"text": "A single - dose , placebo - controlled study of the fully human anti - TNF antibody adalimumab ( D2E7 ) in patients with rheumatoid arthritis .", "label": "", "metadata": {}, "score": "69.87667"}
{"text": "Details of the study designs and populations have previously been published [ 12 - 15 ] .Study 1 ( LVHJ ) was a randomized , double - blind , placebo - controlled , parallel - design multinational study to evaluate the efficacy and safety of daily tadalafil 5 mg once daily for 12 weeks .", "label": "", "metadata": {}, "score": "69.901146"}
{"text": "Mellis , Stahl , Yancopoulos , Soo , Weinstein , and Radin and Ms King - Davis own stock in Regeneron .Dr. Mellis holds a patent , licensed to Regeneron , for the use of interleukin-1 antagonists to treat gout .", "label": "", "metadata": {}, "score": "69.93204"}
{"text": "21 - 856 , indication : treatment of hyperurice- mia in patients with gout .Briefing document for Advisory Com- mittee , Division of Anesthesia , Analgesia , and Rheumatology Products , FDA Advisory Committee Meeting , November 24 , 2008 .", "label": "", "metadata": {}, "score": "69.9998"}
{"text": "P values were determined by Wilcoxon 's rank sum test .B , Kaplan - Meier curve of the time to first gout flare from day 1 to week 16 ( full analysis set ) .", "label": "", "metadata": {}, "score": "70.11279"}
{"text": "A treatment - emergent event was defined as an adverse event that occurred during the period from the first dose to 42 days ( 6 weeks ) after the final dose of the study drug .", "label": "", "metadata": {}, "score": "70.21628"}
{"text": "However , there are no studies confirming the utility of these lower dosages , while there is support for initial use of 300 mg per day ( 22 ) , which is the dosage often initiated in clinical practice .", "label": "", "metadata": {}, "score": "70.230286"}
{"text": "One such instrument is the International Prostate Symptom Score ( IPSS ) which is commonly used to assess therapeutic efficacy of BPH therapy [ 3 , 4 ] and has been translated into multiple languages .", "label": "", "metadata": {}, "score": "70.24026"}
{"text": "One such instrument is the International Prostate Symptom Score ( IPSS ) which is commonly used to assess therapeutic efficacy of BPH therapy [ 3 , 4 ] and has been translated into multiple languages .", "label": "", "metadata": {}, "score": "70.24026"}
{"text": "In phase-3 clinical trials , the interleukin ( IL-1 ) blocker , rilonacept ( IL-1 Trap ) , demonstrated efficacy for gout flare prevention during initiation of urate - lowering therapy .", "label": "", "metadata": {}, "score": "70.26731"}
{"text": "Paradoxically , initiation of urate- lowering therapy can elicit a gout attack , likely due to remodeling of crystal deposits during dissolution ( 3 ) .", "label": "", "metadata": {}, "score": "70.31659"}
{"text": "Modified disease activity scores that include twenty - eight - joint counts .Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis .", "label": "", "metadata": {}, "score": "70.51129"}
{"text": "Competing interests .All the authors are employees of Eli Lilly and Company , the manufacturer of Cialis \u00ae , a PDE5-inhibitor , which is approved in USA , EU and other geographies around the world for the treatment of ED , BPH - LUTS ( signs and symptoms of BPH ) and ED / BPH - LUTS .", "label": "", "metadata": {}, "score": "70.52732"}
{"text": "Acorda Therapeutics Presents Data from its Phase 3 Study of Fampridine - SR in Multiple Sclerosis at the American Academy of Neurology Meeting . 03May 2007 .", "label": "", "metadata": {}, "score": "70.57343"}
{"text": "The benefits of tocilizumab therapy were seen as early as week 4 , and were sustained to 24 weeks of treatment .At 1 week , while patient - reported measures were significantly improved , physician - reported measures of global disease activity , tender and swollen joint counts were not .", "label": "", "metadata": {}, "score": "70.74199"}
{"text": "No serious drug - related ad- verse events were reported , and injection site reactions ( none leading to withdrawal ) were the most common treatment - related event .", "label": "", "metadata": {}, "score": "70.78573"}
{"text": "Ezzo J , Hadhazy V , Birch S , Lao L , Kaplan G , Hochberg M , et al .Page 9 . ture for osteoarthritis of the knee : a systematic review .", "label": "", "metadata": {}, "score": "70.82349"}
{"text": "OMERACT Committee .J Rheumatol .[ PMID : 8478874 ] 23 .Collins SL , Edwards J , Moore RA , Smith LA , McQuay HJ .", "label": "", "metadata": {}, "score": "70.907166"}
{"text": "Overall , most patients were women and were white , with a mean age of approximately 55 years and a mean duration of RA of 8.5 years .", "label": "", "metadata": {}, "score": "70.91133"}
{"text": "Wallace SL , Robinson H , Masi AT , Decker J , McCarty DJ , Yu TF .Preliminary criteria for the classification of the acute arthritis of primary gout .", "label": "", "metadata": {}, "score": "70.99327"}
{"text": "Acknowledgments : The authors thank Albrecht Molsberger , MD , for supporting the development of the acupuncture schemes and Christina Klose for data management .Potential Financial Conflicts of Interest : Grants received : C. Maier , H.-J. Trampisch , N. Victor ( Consortium of Allgemeine Ortskrankenkassen , Betriebskrankenkassen , Innungskrankenkassen , Landwirtschaftliche Krankenkassen , and See - Krankenkassen ) .", "label": "", "metadata": {}, "score": "71.047195"}
{"text": "Weinblatt ME , Kremer JM , Bankhurst AD , Bulpitt KJ , Fleischmann RM , Fox RI , et al .A trial of etanercept , a recombinant tumour necrosis factor receptor : Fc fusion protein , in patients with rheumatoid arthritis receiving methotrexate .", "label": "", "metadata": {}, "score": "71.05275"}
{"text": "Intensive treatment with methotrexate in early rheumatoid arthritis : aiming for remission .Computer Assisted Management in Early Rheumatoid Arthritis ( CAMERA , an open - label strategy trial ) .", "label": "", "metadata": {}, "score": "71.101265"}
{"text": "Eligible patients participated in an open - label two - week phase in which they stopped drug therapy with previously prescribed analgesics .In this phase patients started drug therapy that consisted of a 70 mcg buprenorphine ( BUP ) transdermal ( TDS ) patch applied every three days .", "label": "", "metadata": {}, "score": "71.11856"}
{"text": "The lead authors reviewed and contributed to the interpretation of the results and agreed to prepare and submit the manuscript for publication , with technical writing and editorial assistance from a professional medical writer , E. Jay Bienen , PhD , and Regeneron .", "label": "", "metadata": {}, "score": "71.15752"}
{"text": "Maximal ACR50 response for the adalimumab groups ( by ascending dose ) was attained by week 12 ( 17 , 24 % ) , week 10 ( 20 , 29 % ) , and week 8 ( 14 , 19 % ) , respectively .", "label": "", "metadata": {}, "score": "71.17115"}
{"text": "Annual Rev Psychol .International Conference on Harmonization .Note for Guidance on Statisti- cal Principles for Clinical Trials .Topic E9 .London : European Medicines Agen- cy ; 1998:CPMP / ICH/363/96 .", "label": "", "metadata": {}, "score": "71.19614"}
{"text": "Negative changes in WOMAC score indicate improvement ; negative WOMAC changes favor the first group .TCA ? traditional Chinese acupuncture ; WOMAC ?Western Ontario and McMaster Universities Osteoarthritis Index .", "label": "", "metadata": {}, "score": "71.2601"}
{"text": "Abrams P , Cardozo L , Fall M , Griffiths D , Rosier P , Ulmsten U , van Kerrebroeck P , Victor A , Wein A : Standardisation Sub - committee of the International Continence Society .", "label": "", "metadata": {}, "score": "71.26569"}
{"text": "Study participants generally had severe , recalcitrant , long term RA .Despite prior treatment with an average of nearly four traditional DMARDs , these patients continued to exhibit persistent disease activity , including large numbers of tender and swollen joints , thus placing them at risk of further joint destruction and worsening disability .", "label": "", "metadata": {}, "score": "71.423294"}
{"text": "Yokoyama O , Yoshida M , Kim SC , Wang C - J , Imaoka T , Morisaki Y , Viktrup L : Efficacy and safety of tadalafil in Asian men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia : A phase III randomized controlled study .", "label": "", "metadata": {}, "score": "71.48185"}
{"text": "While rilonacept treatment was not associated with a higher rate of infections compared with placebo in this modest - sized study , it remains possible that , as with other IL-1 inhibitors , rilonacept might be associated with an increased risk of certain types of infections .", "label": "", "metadata": {}, "score": "71.498245"}
{"text": "We , however , focused on the effect of repeated acupuncture treatment specifically on brain regions known to support functions dysregulated in chronic pain disorders .", "label": "", "metadata": {}, "score": "71.508064"}
{"text": "Seven neoplasms were reported , four in the tocilizumab group and three in the placebo group .In the placebo group , there was one report of non - melanoma skin cancer ( squamous cell carcinoma of left cheek in situ , day 116 ) ; one diffuse large B - cell lymphoma ( day 170 ) and one renal cell carcinoma ( day 40 ) .", "label": "", "metadata": {}, "score": "71.568634"}
{"text": "Appendix Table 6 . 326 ) , n ( % )Sham Acupuncture Group ( n ? 265 ) , n ( % ) Conservative Therapy Group ( n ? 316 ) , n ( % ) Total ( n ?", "label": "", "metadata": {}, "score": "71.56903"}
{"text": "Further eval- uation of the use of IL-1 blockade for both the preven- tion and the treatment of acute gout flares is warranted .AUTHOR CONTRIBUTIONS All authors were involved in drafting the article or revising it critically for important intellectual content , and all authors approved the final version to be published .", "label": "", "metadata": {}, "score": "71.6678"}
{"text": "330 mg in this study at weeks 12 and 16 , the target urate level was not achieved in 30 - 40 % of patients ; in contrast , in the FACT trial , serum urate levels ?", "label": "", "metadata": {}, "score": "71.726425"}
{"text": "This study shows that repeated verum acupuncture might act by restoring the balance in the connectivity of the key pain brain regions , altering pain - related attention and memory .", "label": "", "metadata": {}, "score": "71.750114"}
{"text": "The 40 mg and 80 mg doses provided similar benefit .Adalimumab at all doses was generally well tolerated , with only mild or moderate adverse events .", "label": "", "metadata": {}, "score": "71.79727"}
{"text": "The investigator judged the death unlikely to be related to the study drug .No drug related toxicity was indicated by haematology , coagulation , clinical chemistry , or urine analysis evaluations .", "label": "", "metadata": {}, "score": "71.806915"}
{"text": "ED was an entry criterion only in Study 2 ( LVHR ) .The 4 studies were in compliance with the Helsinki Declaration .In each study , participants were screened at V1 .", "label": "", "metadata": {}, "score": "71.88892"}
{"text": "pdf .Angalakuditi M , Seifert RF , Hayes RP , O'Leary MP , Viktrup L , Measurement properties of the benign prostatic hyperplasia impact index in tadalafil studiesHealth Qual Life Outcomes Year : 2010813110.1186/1477 - 7525 - 8 - 13121073697 .", "label": "", "metadata": {}, "score": "71.92311"}
{"text": "hibited treatments , \" and \" change of treatment group , \" in- dicated treatment failure .Redefinition of the primary end point using these events did not alter the general conclu- sions .", "label": "", "metadata": {}, "score": "71.9364"}
{"text": "However , because complete blinding was im- possible , this study does not allow us to determine whether the observed effectiveness of TCA and sham acupuncture was due to placebo effects , intensity of provider contact , or a physiologic effect of needling .", "label": "", "metadata": {}, "score": "72.04236"}
{"text": "Four neoplasms were reported in the tocilizumab group and three in the placebo group ; there were no cases of gastrointestinal perforations in either arm .", "label": "", "metadata": {}, "score": "72.19803"}
{"text": "The encouraging results of that study motivated this further investigation .We evaluated rilonacept for its efficacy in pre- venting acute gout flares during initiation of urate- lowering therapy .", "label": "", "metadata": {}, "score": "72.28697"}
{"text": "The AUA committee also developed the BPH Impact Index ( BII ) to assess the impact of LUTS suggestive of BPH on patient health and functioning [ 4 ] .", "label": "", "metadata": {}, "score": "72.30065"}
{"text": "The AUA committee also developed the BPH Impact Index ( BII ) to assess the impact of LUTS suggestive of BPH on patient health and functioning [ 4 ] .", "label": "", "metadata": {}, "score": "72.30065"}
{"text": "den Broeder AA , Joosten LAB , Saxne T , Heinegard D , Fenner H , Miltenburg AM , et al .Long term anti - tumour necrosis factor \u03b1 monotherapy in rheumatoid arthritis : effect on radiological course and prognostic value of markers of cartilage turnover and endothelial activation .", "label": "", "metadata": {}, "score": "72.49964"}
{"text": "Am J Med 2002 ; 113 : 188 -93 .To evaluate the interleukin-1 inhibitor rilonacept ( Interleukin-1 Trap ) for prevention of gout flares occurring in the first few months following initiation of urate - lowering therapy .", "label": "", "metadata": {}, "score": "72.5136"}
{"text": "Appendix Table 1 . 326 ) Sham Acupuncture Group ( n ?365 ) Conservative Therapy Group ( n ? nonsteroidal anti - inflammatory drug .", "label": "", "metadata": {}, "score": "72.565285"}
{"text": "[ PMID : 11501727 ] 16 .Stux G , Birch S. Proposed standards of acupuncture treatment for clinical studies .In : Stux G , Hammerschlag R , eds .", "label": "", "metadata": {}, "score": "72.56656"}
{"text": "Pascual E , Sivera F. Time required for disappearance of urate crystals from synovial fluid after successful hypouricaemic treat- ment relates to the duration of gout .", "label": "", "metadata": {}, "score": "72.76399"}
{"text": "Andrew Goodman , M.D. , Director of the Multiple Sclerosis Center at the University of Rochester , presented top - line results on walking ability , leg strength , spasticity and clinician and subject global impressions .", "label": "", "metadata": {}, "score": "72.86573"}
{"text": "One study ( Study 3 , LVHB ) also required a minimum total prostate volume of 20 mL. V3 ( randomization ) initiated the double - blind active - treatment placebo - controlled 12-week period .", "label": "", "metadata": {}, "score": "72.93799"}
{"text": "Marcus R , Peritz E , Gabriel KR .On closed testing procedures with special reference to ordered analysis of variance .Biometrika .Shaffer JP .", "label": "", "metadata": {}, "score": "72.97201"}
{"text": "When acupuncture did not reduce the pain to a level the patient found acceptable , patients could take up to 150 mg of diclofenac per day during the first 2 treat- ment weeks and up to a total of 1 g until week 23 .", "label": "", "metadata": {}, "score": "73.3524"}
{"text": "Psoriatic Arthritis .October 26 , 2015 .Novartis has issued results of a phase III study of secukinumab for psoriatic arthritis ( PsA ) .", "label": "", "metadata": {}, "score": "73.367645"}
{"text": "41 ] ) and week 16 ( 6.4 ? 1.6 mg / dl [ n ? 42 ] versus 5.9 ? 1.4 mg / dl [ n ?", "label": "", "metadata": {}, "score": "73.39078"}
{"text": "Any flare 1 flare ? not determined .880 SCHUMACHER ET AL .Page 6 . rilonacept - treated patients reported more than 1 flare during this period ( P ?", "label": "", "metadata": {}, "score": "73.45315"}
{"text": "SF-12 ?12-item Short - Form Health Survey ; WOMAC ?Western Ontario and McMaster Universities Osteoarthritis Index .Page 7 . affect the statistical significance of the group differences .", "label": "", "metadata": {}, "score": "73.4718"}
{"text": "( Note : Please see supplementary appendix , available online only , for additional information on RAPID3 scores during the first week of treatment . )", "label": "", "metadata": {}, "score": "73.50885"}
{"text": "Conservative therapy is taken as baseline , and corresponding odds for treatment success are given .TCA ? traditional Chinese acupuncture ; WOMAC ?Western Ontario and McMaster Universities Osteoarthritis Index .", "label": "", "metadata": {}, "score": "73.55858"}
{"text": "[ PMID : 11900500 ] 32 .Witt C , Brinkhaus B , Jena S , Linde K , Streng A , Wagenpfeil S , et al .", "label": "", "metadata": {}, "score": "73.599594"}
{"text": "Arthritis Rheum 1995 ; 38 : 727 -35 .Svenson KL , Lithell H , Hallgren R , Vessby B. Serum lipoprotein in active rheumatoid arthritis and other chronic inflammatory arthritides .", "label": "", "metadata": {}, "score": "73.611336"}
{"text": "Journal of Pain and Symptom Management , 36 ( 2 ) , 117 - 125 .Study Purpose : .To investigate the analgesic efficacy and safety of a transdermal buprenorphine patch used by patients with chronic severe cancer pain .", "label": "", "metadata": {}, "score": "73.620384"}
{"text": "Background .Lower urinary tract symptoms ( LUTS ) , often associated with benign prostatic hyperplasia ( BPH ) , are common in aging men worldwide with a severity that seems to be similar across countries [ 1 ] .", "label": "", "metadata": {}, "score": "73.63751"}
{"text": "E - mail : schumacr@mail.med.upenn.edu .Submitted for publication January 21 , 2011 ; accepted in revised form October 6 , 2011 .Page 2 . setting of hyperuricemia .", "label": "", "metadata": {}, "score": "73.683685"}
{"text": "One potential limitation of this study is the initiation of allopurinol starting at a dosage of 300 mg daily ( in patients with normal renal function ) .", "label": "", "metadata": {}, "score": "73.75575"}
{"text": "Schumacher , Terkeltaub , Stahl , Yancopoulos , Soo , Weinstein , Radin .ROLE OF THE STUDY SPONSOR Regeneron Pharmaceuticals , Inc. designed the study in col- laboration with the academic authors .", "label": "", "metadata": {}, "score": "73.77939"}
{"text": "Arnold LM , Clauw D , Wang F , Ahl J , Gaynor PJ , Wohlreich MM , Flexible dosed duloxetine in the treatment of fibromyalgia : a randomized , double - blind , placebo - controlled trialJ Rheumatol Year : 201037122578258610.3899/jrheum.10036520843911 . x21981682 .", "label": "", "metadata": {}, "score": "73.83101"}
{"text": "Corticosteroids and other analgesics be- sides diclofenac and rofecoxib were explicitly excluded for all patients .Injections , infiltrations , moxibustion , cupping , and electroacupuncture were also prohibited .", "label": "", "metadata": {}, "score": "73.86134"}
{"text": "In contrast to the FACT , an increase in flare rate was not seen in the current study when prophylaxis with rilonacept was discontinued after week 16 , suggesting that a 16-week period of prophylaxis with rilonacept was sufficient for some patients in this study population .", "label": "", "metadata": {}, "score": "73.903786"}
{"text": "[ PMID :7554563 ] 9 .Kellgren JH , Lawrence JS .Radiological assessment of osteo - arthrosis .Ann Rheum Dis .[ PMID : 13498604 ] 10 .", "label": "", "metadata": {}, "score": "73.92068"}
{"text": "[ PMID : 1408309 ] 13 .Streitberger K , Witte S , Mansmann U , Knauer C , Kra \u00a8mer J , Scharf HP , et al .", "label": "", "metadata": {}, "score": "73.92989"}
{"text": "Hande KR , Noone RM , Stone WJ .Severe allopurinol toxicity : description and guidelines for prevention in patients with renal insufficiency .Am J Med 1984;76:47 - 56 .", "label": "", "metadata": {}, "score": "74.14137"}
{"text": "In this study , we investigated cortical thickness and functional connectivity across longitudinal acupuncture treatments in patients with knee osteoarthritis ( OA ) .Over a period of four weeks ( six treatments ) , we collected resting state functional magnetic resonance imaging ( fMRI ) scans from 30 patients before their first , third and sixth treatments .", "label": "", "metadata": {}, "score": "74.1627"}
{"text": "Ann Intern Med .[ PMID : 12044130 ] 31 .Moerman DE , Jonas WB .Deconstructing the placebo effect and finding the meaning response .", "label": "", "metadata": {}, "score": "74.16792"}
{"text": "Laboratory AEs were automatically generated from CTC grade changes regardless of their clinical relevance .Additionally , AEs necessitating or prolonging hospitalisation , placing the patient at risk of death , or resulting in death , permanent or significant disability , congenital anomaly / birth defect , or other medically important conditions were categorised as serious AEs .", "label": "", "metadata": {}, "score": "74.17247"}
{"text": "Early combination disease - modifying antirheumatic drug therapy and tight disease control improve long - term radiologic outcome in patients with early rheumatoid arthritis : the 11-year results of the Finnish Rheumatoid Arthritis Combination Therapy trial .", "label": "", "metadata": {}, "score": "74.20207"}
{"text": "J Urol 1992 , 148 ( 5 ) : 1549 - 1557 .PubMed .Barry MJ : Evaluation of symptoms and quality of life in men with benign prostatic hyperplasia .", "label": "", "metadata": {}, "score": "74.2583"}
{"text": "Andrew Blight , Ph .D , Chief Scientific Officer of Acorda Therapeutics , commented , \" Walking impairment is one of the most pervasive and serious disabilities afflicting people with MS , and there are no currently approved therapies that are indicated to improve walking in this population .", "label": "", "metadata": {}, "score": "74.259674"}
{"text": "In follow - up visits , at two and four weeks after the end of the treatment period , Responder and Non - responder groups returned to their baseline walking speeds .", "label": "", "metadata": {}, "score": "74.29795"}
{"text": "All authors assume responsibility for the overall content and vouch for the validity and completeness of the reported results .REFERENCES 1 .Bieber JD , Terkeltaub RA .", "label": "", "metadata": {}, "score": "74.36134"}
{"text": "Of all patients , 42.9 % were female and 57.1 % were male .Of all patients , 73 % had metastatic disease .The most frequent metastases were to bone , liver , and lung .", "label": "", "metadata": {}, "score": "74.37569"}
{"text": "Third Report of the National Cholesterol Education Program ( NCEP ) Expert Panel on Detection , Evaluation , and Treatment of High Blood Cholesterol in Adults ( Adult Treatment Panel III)ATP III Final Report .", "label": "", "metadata": {}, "score": "74.39567"}
{"text": "The TCA scheme used in our study was based on different acupuncture schools .We can not be completely sure , however , that there are no active points outside our TCA scheme and that no active point was included in our sham acupuncture scheme .", "label": "", "metadata": {}, "score": "74.41026"}
{"text": "Please refer to this study by its ClinicalTrials.gov identifier : NCT00464191 .Bipolar Disorder Affective Disorders , Psychotic Mental Disorders Mood Disorders Citalopram Dexetimide Anti - Dyskinesia Agents Antidepressive Agents Antidepressive Agents , Second - Generation Antiparkinson Agents Autonomic Agents Central Nervous System Agents Cholinergic Agents .", "label": "", "metadata": {}, "score": "74.447365"}
{"text": "JRC has received research grants and consulting fees from Amgen , Centocor , Corrona , Abbott , Roche and UCB .AI is a speaker for Amgen and Wyeth Pharmaceuticals .", "label": "", "metadata": {}, "score": "74.730705"}
{"text": "Neurourol Urodyn 2002 , 21 ( 2 ) : 167 - 178 .PubMed View Article .Barry MJ , Fowler FJ Jr , O'Leary MP , Bruskewitz RC , Holtgrewe HL , Mebust WK , Cockett AT : The American Urological Association symptom index for benign prostatic hyperplasia .", "label": "", "metadata": {}, "score": "74.7655"}
{"text": "Across all groups , the most frequent AEs were headache and dizziness .Although generally well - tolerated , rilonacept in combination with indomethacin and rilonacept alone did not provide additional pain relief over 72 hours relative to indomethacin alone in patients with acute gout flare .", "label": "", "metadata": {}, "score": "74.88412"}
{"text": "Data provided are for informational purposes only .Although carefully collected , accuracy can not be guaranteed .The impact factor represents a rough estimation of the journal 's impact factor and does not reflect the actual current impact factor .", "label": "", "metadata": {}, "score": "74.925385"}
{"text": "All patients provided written informed consent prior to enrollment .To be eligible for enrollment , patients had to be ?18 years of age and to have previously met the American College of Rheumatology preliminary criteria for the classification of acute arthritis of primary gout ( 15 ) , based on clinical features and/or demonstration of MSU crystals in joint fluid .", "label": "", "metadata": {}, "score": "74.946915"}
{"text": "RILONACEPT FOR GOUT FLARE PREVENTION883 .Page 9 .Torres R , Macdonald L , Croll SD , Reinhardt J , Dore A , Stevens S , et al .", "label": "", "metadata": {}, "score": "75.165794"}
{"text": "Canakinumab reduces the risk of acute gouty arthritis flares during initiation of allopurinol treatment : results of a double - blind , randomized study .Ann Rheum Dis 2011;70 : 1264 - 71 .", "label": "", "metadata": {}, "score": "75.52623"}
{"text": "All authors read and approved the final manuscript .Authors ' Affiliations .Lilly Research Laboratories , Eli Lilly and Company .References .Int J Urol 1997 , 4 : 40 - 46 .", "label": "", "metadata": {}, "score": "75.55606"}
{"text": "Additional phase III trials are ongoing at this time .Study design : Prospective , randomised , placebo - controlled parallel - group multicenter study .", "label": "", "metadata": {}, "score": "75.59042"}
{"text": "A 65 year old man taking adalimumab 80 mg died of a myocardial infarction on day 86 of the study .This patient , who had pre - existing cardiac disease and cardiovascular risk factors , was at increased risk of myocardial infarction and was treated with the antihypertensive amlodipine .", "label": "", "metadata": {}, "score": "75.63766"}
{"text": "Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active , early , moderate to severe rheumatoid arthritis ( COMET ) : a randomised , double - blind , parallel treatment trial .", "label": "", "metadata": {}, "score": "75.66833"}
{"text": "Vali- dation study of WOMAC : a health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee .", "label": "", "metadata": {}, "score": "75.66886"}
{"text": "Statistical expertise : U. Mansmann , S. Witte , N. Victor .Obtaining of funding : C. Maier , H.-J. Trampisch , N. Victor .Administrative , technical , or logistic support : S. Witte , C. Maier , H.-J. Trampisch , N. Victor .", "label": "", "metadata": {}, "score": "75.83845"}
{"text": "Prospective investigation of adverse effects of acupuncture in 97 733 pa- tients .Arch Intern Med .[ PMID : 14718331 ] 30 .Kaptchuk TJ .", "label": "", "metadata": {}, "score": "75.85919"}
{"text": "Schumacher HR , Taylor W , Joseph - Ridge N , Perez - Ruiz F , Chen LX , Schlesinger N , et al .Outcome evaluations in gout .", "label": "", "metadata": {}, "score": "75.91972"}
{"text": "Santora LC , Kaymak\u00e7alan Z , Sakorafas P , Krull IS , Grant K. Characterization of noncovalent complexes of recombinant human monoclonal antibody and antigen using cation exchange , size exclusion chromatography , and BIAcore .", "label": "", "metadata": {}, "score": "75.94306"}
{"text": "Santora LC , Krull IS , Grant K. Characterization of recombinant human monoclonal tissue necrosis factor - \u03b1 antibody using cation - exchange HPLC and capillary isoelectric focusing .", "label": "", "metadata": {}, "score": "76.16507"}
{"text": "Comparison of rilonacept monotherapy with indomethacin monotherapy was dependent on demonstration of significance for the primary endpoint .Safety evaluation included clinical laboratory and adverse event ( AE ) assessments .", "label": "", "metadata": {}, "score": "76.16973"}
{"text": "Study medication is dispensed .The patients will return to further visits as shown below .Patients will receive study medication for a maximum of 40 weeks .", "label": "", "metadata": {}, "score": "76.25478"}
{"text": "Full - text .Objective : To assess the efficacy and safety of traditional Chinese acupuncture ( TCA ) compared with sham acupuncture ( needling at defined nonacupuncture points ) and conservative therapy in pa- tients with chronic pain due to osteoarthritis of the knee .", "label": "", "metadata": {}, "score": "76.25635"}
{"text": "Biannual radiographic assessments of hands and feet in a three - year prospective followup of patients with early rheumatoid arthritis .Arthritis Rheum 1992 ; 35 : 26 -34 .", "label": "", "metadata": {}, "score": "76.27672"}
{"text": "Arthritis Rheum 1993 ; 36 : 729 -40 .Felson DT , Anderson JJ , Boers M , Bombardier C , Furst D , Goldsmith C , et al .", "label": "", "metadata": {}, "score": "76.27753"}
{"text": "Early phase I trials have demonstrated that adalimumab produces rapid and significant responses in patients with DMARD refractory active RA and suppresses long term radiological progression .", "label": "", "metadata": {}, "score": "76.27773"}
{"text": "Treatment was generally well tolerated .November 19 , 2007 .Cypress and Forest issued positive composite responder results two phase III trials of milnacipran for the treatment of fibromyalgia .", "label": "", "metadata": {}, "score": "76.3618"}
{"text": "So A , DeSmedt T , Revaz S , Tschopp J. A pilot study of IL-1 inhibition by anakinra in acute gout .Arthritis Res Ther 2007;9 : R28 .", "label": "", "metadata": {}, "score": "76.501274"}
{"text": "Economides AN , Carpenter LR , Rudge JS , Wong V , Koehler - Stec EM , Hartnett C , et al .Cytokine traps : multi - component , high- affinity blockers of cytokine action .", "label": "", "metadata": {}, "score": "76.85181"}
{"text": "DISCUSSION .Adalimumab is the first fully human monoclonal antibody to TNF\u03b1 to enter clinical trials for the treatment of RA .Early phase I / II trial results with adalimumab monotreatment have been very encouraging .", "label": "", "metadata": {}, "score": "76.86182"}
{"text": "( % ) White Black Other Body mass index , kg / m2 Duration of gout , years Serum urate concentration , mg / dl Presence of tophi , no .", "label": "", "metadata": {}, "score": "77.02971"}
{"text": "Study participants were men with LUTS secondary to BPH ( BPH - LUTS ) residing in Argentina , Germany , Italy , Mexico , or the United States ( Clinicaltrials.gov : NCT00827242 [ 12 ] ) .", "label": "", "metadata": {}, "score": "77.042564"}
{"text": "ARTHRITIS & RHEUMATISM Vol .To evaluate the interleukin-1 inhibitor rilonacept ( Interleukin-1 Trap ) for prevention of gout flares occurring in the first few months following initi- ation of urate - lowering therapy .", "label": "", "metadata": {}, "score": "77.07372"}
{"text": "METHODS .Protocol .This phase II study was a 12 week , double blind , placebo controlled , multicentre trial conducted at 25 sites across nine European countries in accordance with the Good Clinical Practice Guidelines and principles of the Declaration of Helsinki .", "label": "", "metadata": {}, "score": "77.12277"}
{"text": "Men who were at least 45 years of age , with moderate to severe LUTS due to BPH and evidence of bladder obstruction , were eligible to participate in all 4 studies .", "label": "", "metadata": {}, "score": "77.1667"}
{"text": "Rheumatology ( Oxford ) .[ PMID : 10378713 ] 18 .Christensen BV , Iuhl IU , Vilbek H , Bu \u00a8low HH , Dreijer NC , Rasmussen HF .", "label": "", "metadata": {}, "score": "77.366844"}
{"text": "Arthritis Rheum 1998 ; 41 : S57 ( abstr 149 ) .Rau R , Sander O , den Broeder A , van Riel PLCM , van de Putte LBA , Kr\u00fcger K , et al .", "label": "", "metadata": {}, "score": "77.38373"}
{"text": "A maximum of 4 Ahshi points was also allowed ( Table 1 ) .Sham acupuncture was standardized as minimal - depth needling without stimulation at 10 points at defined dis- tances from TCA points .", "label": "", "metadata": {}, "score": "77.51598"}
{"text": "333 ) Sham Acupuncture Group ( n ?358 ) Total ( n ?Seven patients in the sham acupuncture group were treated with traditional Chinese acupuncture .", "label": "", "metadata": {}, "score": "77.60129"}
{"text": "The analyses were performed with SAS , version 8.2 ( SAS Institute , Inc. , Cary , North Carolina ) .The mixed- effects models were run by using the SAS macro GLIM- MIX with the maximum likelihood option .", "label": "", "metadata": {}, "score": "77.6102"}
{"text": "Key inclusion criteria for the study included the ability to complete the Timed 25 Foot Walk twice at screening with times averaging between 8 and 45 seconds , having a confirmed diagnosis of MS and having a stable condition .", "label": "", "metadata": {}, "score": "77.62645"}
{"text": "Multiple randomized clinical trials have suggested that knee OA patients can benefit from acupuncture treatment9111213 .However , the mechanisms underlying the effects of acupuncture treatment in knee OA patients are still poorly understood .", "label": "", "metadata": {}, "score": "77.665054"}
{"text": "Presentation Highlights .The prospectively - designed analysis plan for the study was based on a responder criterion , defined as a consistent improvement in walking speed , as measured with the Timed 25 Foot Walk .", "label": "", "metadata": {}, "score": "77.74"}
{"text": "Patients could request up to 5 additional sessions or visits if the initial treatment was viewed as being partially successful .Success rate , as defined by at least 36 % improvement in Western Ontario and McMaster Universities Osteoarthritis Index ( WOMAC ) score at 26 weeks .", "label": "", "metadata": {}, "score": "77.84749"}
{"text": "Clas- sification of osteoarthritis of the knee .Diagnostic and Therapeutic Criteria Com- mittee of the American Rheumatism Association .Arthritis Rheum .[ PMID : 3741515 ] 22 .", "label": "", "metadata": {}, "score": "78.054726"}
{"text": "Lan- cet .[ PMID : 16005336 ] 33 .Berman BM , Lao L , Langenberg P , Lee WL , Gilpin AM , Hochberg MC .", "label": "", "metadata": {}, "score": "78.05524"}
{"text": "[ PMID :10730371 ] 4 .Felson DT , Lawrence RC , Hochberg MC , McAlindon T , Dieppe PA , Mi- nor MA , et al .", "label": "", "metadata": {}, "score": "78.31063"}
{"text": "Arthritis Rheum 2004;50:2400 - 14 .Schumacher HR , Chen LX .The practical management of gout .Cleve Clin J Med 2008;75 Suppl 5:S22 - 5 .", "label": "", "metadata": {}, "score": "78.66927"}
{"text": "Conclusions This study demonstrated the efficacy of tocilizumab in improving measures of disease activity in patients with RA who failed to respond adequately to DMARD therapy .", "label": "", "metadata": {}, "score": "78.81099"}
{"text": "In recent times , biological DMARD treatments for RA have been developed to inhibit the activity of proinflammatory cytokines such as tumour necrosis factor \u03b1 ( TNF\u03b1 ) , which mediates the destructive synovitis that is the hallmark of RA .", "label": "", "metadata": {}, "score": "78.836945"}
{"text": "SE Mean change from baseline at week 13 ( 95 % CI ) Mean change from baseline at week 26 ( 95 % CI ) 30.5 ? 0.87 [ 4 ] 6.4 ( 4.3 to 8.5 ) [", "label": "", "metadata": {}, "score": "78.90585"}
{"text": "SE Mean change from baseline at week 13 ( 95 % CI ) Mean change from baseline at week 26 ( 95 % CI ) 48.9 ? 1.58 [ 4 ] 2.1 ( 0.9 to 3.3 ) [", "label": "", "metadata": {}, "score": "78.93516"}
{"text": "Part 2 : treatment approaches .Ann Intern Med .[ PMID : 11074906 ] 5 .NIH Consensus Conference .Acupuncture .JAMA .[ PMID :", "label": "", "metadata": {}, "score": "79.011986"}
{"text": "Febuxostat compared with allopurinol in patients with hyperuricemia and gout .N Engl J Med 2005;353 : 2450 - 61 .Takeda Pharmaceuticals North America Inc.", "label": "", "metadata": {}, "score": "79.06991"}
{"text": "[ PMID :3068365 ] 11 .Stucki G , Meier D , Stucki S , Michel BA , Tyndall AG , Dick W , et al .", "label": "", "metadata": {}, "score": "79.095245"}
{"text": "New York : McGraw - Hill ; 1973 .Lepor H , Williford WO , Barry MJ , Haakenson C , Jones K : The impact of medical therapy on bother due to symptoms , quality of life and global outcome , and factors predicting response .", "label": "", "metadata": {}, "score": "79.114456"}
{"text": "One point was on the highest spot of the tightened mus- culus biceps brachii .This control technique was chosen to minimize any supposed nonspecific antinociceptive physi- ologic effects of deep needling and strong stimulation , in- cluding the typical acupuncture sensation of deqi . Nonin-", "label": "", "metadata": {}, "score": "79.28931"}
{"text": "METHODS Participants A total of 1039 eligible patients were enrolled in the study between April 2002 and March 2004 .The ethics committees of the University of Heidelberg and the University of Mannheim and all involved local ethics committees approved the study .", "label": "", "metadata": {}, "score": "79.36075"}
{"text": "Acupuncture could improve conservative therapy and re- duce the use of analgesics .Further investigation is neces- sary to determine whether the mechanism of the observed effect of acupuncture is due to physiologic effects of nee- dling , intensity of provider contact , or placebo effects .", "label": "", "metadata": {}, "score": "79.52454"}
{"text": "Implications Acupuncture ( traditional or sham ) was more effective than medical management alone .Needling alone , even in non-traditional insertion sites ; more intensive medical attention ; or placebo effects may be responsible for this result .", "label": "", "metadata": {}, "score": "79.68625"}
{"text": "According to the steadily increasing attention on gout , due to well - established prognostic and epidemiology implications , in the last 5 years , the same change of perspective has been observed also for this disease .", "label": "", "metadata": {}, "score": "79.84316"}
{"text": "Adalimumab is associated with rapid clinical response rates .In one study , clinically relevant responses were reported to occur at 24 hours to one week after a single intravenous injection of adalimumab .", "label": "", "metadata": {}, "score": "79.881805"}
{"text": "Longitudinal cortical thickness analysis showed that the cortical thickness at left posterior medial prefrontal cortex ( pMPFC ) decreased significantly in the sham group across treatment sessions as compared with verum group .", "label": "", "metadata": {}, "score": "79.937805"}
{"text": "Lower urinary tract symptoms ( LUTS ) , often associated with benign prostatic hyperplasia ( BPH ) , are common in aging men worldwide with a severity that seems to be similar across countries [ 1 ] .", "label": "", "metadata": {}, "score": "80.17767"}
{"text": "December 8 , 2014 .Novartis has reported results of two phase III trials of AIN457 ( secukinumab ) for psoriatic arthritis ( PsA ) .", "label": "", "metadata": {}, "score": "80.2648"}
{"text": "Trial Registry no NCT00531817 .Early and aggressive treatment of rheumatoid arthritis ( RA ) is associated with improved outcomes , including lower disease activity , improved physical function and quality of life and reduced radiographic disease progression .", "label": "", "metadata": {}, "score": "80.31651"}
{"text": "The IL-1 inhibitor rilonacept in treatment of chronic gouty arthritis : results of a placebo - controlled , mono- sequence crossover , nonrandomized , single - blind pilot study .", "label": "", "metadata": {}, "score": "80.51358"}
{"text": "[ PMID : 11315921 ] 7 .Molsberger A , Diener HC , Kra \u00a8mer J , Michaelis J , Scha \u00a8fer H , Trampisch HJ , et al .", "label": "", "metadata": {}, "score": "80.559105"}
{"text": "Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study GroupJ Urol Year : 199816041358136710.1016/S0022 - 5347(01)62536 - 99751354 .FDA GuidanceGuidance for Industry .pdf .", "label": "", "metadata": {}, "score": "80.56253"}
{"text": "7- 9 For this reason , early diagnosis and aggressive treatment are now recognised as essential to the successful long term outcome of the disease .", "label": "", "metadata": {}, "score": "80.79373"}
{"text": "Dr. Streitberger : Department of Anesthesiology , University of Heidel- berg , I m Neuenheimer Feld 100 , D-69120 Heidelberg , Germany .Drs .Witte and Victor : Institute of Medical Biometry and Informatics , University of Heidelberg , I m Neuenheimer Feld 305 , D-69120 Heidel- berg , Germany .", "label": "", "metadata": {}, "score": "80.84591"}
{"text": "Effects of anti - inflammatory and disease - modifying drug treatment .Arch Intern Med 1987 ; 147 : 1917 -20 .Park Y - B , Choi HK , Kim M - Y , Lee W - K , Song J , Kim D - K , et al .", "label": "", "metadata": {}, "score": "81.06797"}
{"text": "Allocation : Randomized Endpoint Classification : Safety / Efficacy Study Intervention Model : Parallel Assignment Masking : Double - Blind Primary Purpose : Treatment .Official Title : .", "label": "", "metadata": {}, "score": "81.19955"}
{"text": "( The source of the bacterial infection was never identified and the fever subsided after five days of antibiotic treatment . )All serious infections resolved or were resolving by week 12 .", "label": "", "metadata": {}, "score": "81.30744"}
{"text": "Advertisement .Who is online .This site does not offer , or claim to offer , medical , legal , or professional advice .All treatment decisions should always be made with the full knowledge of your physicians .", "label": "", "metadata": {}, "score": "81.41538"}
{"text": "Author Contributions : Conception and design : H.-P. Scharf , U. Mans- mann , K. Streitberger , S. Witte , J. Kra \u00a8mer , C. Maier , H.-J. Trampisch , N. Victor .", "label": "", "metadata": {}, "score": "81.780464"}
{"text": "Publisher main menu .Follow BioMed Central .BMC Urology main menu .Construct validation of patient global impression of severity ( PGI - S ) and improvement ( PGI - I ) questionnaires in the treatment of men with lower urinary tract symptoms secondary to benign prostatic hyperplasia .", "label": "", "metadata": {}, "score": "81.98121"}
{"text": "In addition , for most linguistic validations , harmonization , a meeting in which all translations and the original are compared to ensure cross - cultural equivalence of concepts and the use of colloquial language , was performed .", "label": "", "metadata": {}, "score": "82.42645"}
{"text": "In addition , for most linguistic validations , harmonization , a meeting in which all translations and the original are compared to ensure cross - cultural equivalence of concepts and the use of colloquial language , was performed .", "label": "", "metadata": {}, "score": "82.42645"}
{"text": "Competing interests YY has received research grants and consulting fees from Genentech , a member of the Roche Group .He has received consulting fees from Bristol - Myers Squibb , Celgene , Centocor and UCB and has ownership / partnership in UCB .", "label": "", "metadata": {}, "score": "82.94127"}
{"text": "Bei der Granulomatose mit Polyangiitis ( fr\u00fcher M. Wegener ) konnte die bisherige Therapie optimiert werden , die Toxizit\u00e4t wurde reduziert .Dar\u00fcber hinaus hat sich mit Rituximab ein neues Therapeutikum etabliert .", "label": "", "metadata": {}, "score": "83.19252"}
{"text": "Appendix Table 3 . 36 % improvement in the WOMAC score , and treatment failure was ?36 % improvement in the WOMAC score or missing value .", "label": "", "metadata": {}, "score": "83.24248"}
{"text": "PubMed View Article .Eur Urol 2011 , 60 ( 5 ) : 1105 - 1113 .PubMed .J Sex Med 2012 , 9 ( 1 ) : 271 - 281 .", "label": "", "metadata": {}, "score": "83.42504"}
{"text": "SE Mean change from baseline at week 13 ( 95 % CI ) Mean change from baseline at week 26 ( 95 % CI ) 5.4 ? 0.20 [ 0 ] ? 2.4 to ? 1.9 ) [ 12 ] 5.5 ? 0.19", "label": "", "metadata": {}, "score": "83.60213"}
{"text": "15]3.1 ( 1.9 to 4.3 ) [ 8 ] 1.3 ( 0.1 to 2.5 ) [17 ] P ? 0.96P ? 0.36 P ? 0.001 P ? 0.001 P ? 0.001 P ? 0.001 P ? 0.09 P ?", "label": "", "metadata": {}, "score": "83.71884"}
{"text": "Efficacy and safety of rilonacept ( Interleukin-1 Trap ) in patients with cryopyrin - associated periodic syndromes : results from two sequential placebo - controlled studies .", "label": "", "metadata": {}, "score": "83.769196"}
{"text": "Study design and patient population .The Rapid Onset and Systemic Efficacy ( ROSE ) study was a 24-week , randomised , double - blind , placebo - controlled , parallel - group , multicentre phase IIIb clinical trial .", "label": "", "metadata": {}, "score": "84.12715"}
{"text": "Epub ahead of print .LUTS 2011 , 3 ( 2 ) : 86 - 93 .Eur Urol 2006 , 50 ( 6 ) : 1306 - 1315 .", "label": "", "metadata": {}, "score": "84.139885"}
{"text": "1 , 2 Characterised by progressive inflammatory synovitis , RA erodes articular cartilage and marginal bone and destroys joint structure and function , 3 leaving patients with joint deformities , movement problems , and activity limitations .", "label": "", "metadata": {}, "score": "84.38219"}
{"text": "Study participants were men with both ED and BPH - LUTS residing in Canada , France , Germany , Greece , Italy , Mexico , Portugal , Russia , and the United States ( Clinicaltrials.gov : NCT00855582 [ 13 ] ) .", "label": "", "metadata": {}, "score": "84.42728"}
{"text": "Funding This study was funded by Roche .Support for third - party writing assistance for this manuscript , furnished by Marci Mikesell , PhD , was provided by Embryon .", "label": "", "metadata": {}, "score": "84.5677"}
{"text": "Risk and prevention of tuberculosis and other serious opportunistic infections associated with the inhibition of tumor necrosis factor .Nat Clin Pract Rheumatol 2006;2:602 - 10 .", "label": "", "metadata": {}, "score": "84.64508"}
{"text": "The deaths due to sepsis and haemorrhagic stroke were considered by the investigator to be possibly related to study treatment .The death due to coronary artery arteriosclerosis was considered unrelated to treatment .", "label": "", "metadata": {}, "score": "85.05543"}
{"text": "Financial support was given to the Institute of Medical Biometry and Informatics ( Uni- Figure .Study flow diagram .Page 5 . versity of Heidelberg ) ; the Department of Medical Infor- matics , Biometry and Epidemiology ( University of Bo- chum ) ; and the BG - Clinic Bergmannsheil ( University of Bochum ) .", "label": "", "metadata": {}, "score": "85.1121"}
{"text": "Ann Intern Med .For author affiliations , see end of text .Central Registration No . ISRCTN27450856 .Because there is no cure for osteoarthritis , most guidelines recommend a multimodal pharmacologic and nonpharma- cologic approach until total knee replacement is indicated ( 3 , 4 ) .", "label": "", "metadata": {}, "score": "85.15585"}
{"text": "This Is MS Multiple Sclerosis Community : Knowledge & Support .Welcome to the world 's leading forum on Multiple Sclerosis research , support , and knowledge .", "label": "", "metadata": {}, "score": "85.417885"}
{"text": "Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease - modifying antirheumatic drugs : the tocilizumab in combination with traditional disease - modifying antirheumatic drug therapy study .", "label": "", "metadata": {}, "score": "85.48928"}
{"text": "NEC ? not elsewhere classified .RILONACEPT FOR GOUT FLARE PREVENTION881 .Page 7 . to study treatment , and none resulted in treatment discontinuation .", "label": "", "metadata": {}, "score": "85.805466"}
{"text": "Gout attacks typically resolve spontaneously over a period of several days , but MSU crystals remain in the joint space .Recurrent attacks and persistent low - grade inflammation leave patients vulner- able to progressive disease ; without treatment , perma- nent joint destruction can occur ( 1 ) .", "label": "", "metadata": {}, "score": "85.93152"}
{"text": "52 Treatments that reduce inflammation generally effect normalisation in these profiles .52 It has been suggested that altered lipid patterns with untreated active RA may be associated with an increased risk of atherosclerosis 53 ; therefore , effectively controlling the inflammatory state in RA may have additional benefits .", "label": "", "metadata": {}, "score": "86.65672"}
{"text": "SCHUMACHER ET AL .Data provided are for informational purposes only .Although carefully collected , accuracy can not be guaranteed .The impact factor represents a rough estimation of the journal 's impact factor and does not reflect the actual current impact factor .", "label": "", "metadata": {}, "score": "86.66176"}
{"text": "Other conditions mediated by the NLRP3 inflam- masome include a rare group of genetic diseases known as cryopyrin - associated periodic syndromes ( CAPS ) ( 13 ) .", "label": "", "metadata": {}, "score": "86.70408"}
{"text": "Acta Orthop Scand .[ PMID : 7976280 ] 2 . Felson DT .Epidemiology of hip and knee osteoarthritis .Epidemiol Rev. 1988;10:1 - 28 .", "label": "", "metadata": {}, "score": "87.10098"}
{"text": "IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti - tumour necrosis factor biologicals : results from a 24-week multicentre randomised placebo - controlled trial .", "label": "", "metadata": {}, "score": "88.13823"}
{"text": "4 , 5 After 20 years of persistent active RA , nearly 80 % of people are partially disabled and 19 % are completely disabled .", "label": "", "metadata": {}, "score": "88.318275"}
{"text": "Blockade of IL-1 action in animal models by receptor knockout as well as with pharmacologic inhibition has confirmed a role of IL-1 ? in these models of crystal- induced joint pain and inflammation , neutrophil influx , and inflammatory cytokine / chemokine up - regulation ( 9 ) .", "label": "", "metadata": {}, "score": "88.40031"}
{"text": "PubMed View Article .Guy W : ECDEU Assessment Manual for Psychopharmacology .Rockville ( MD ) : National Institute of Mental Health ; 1976:217 - 222 .", "label": "", "metadata": {}, "score": "88.64734"}
{"text": "Postmicturition dribble defined as urine leakage almost immediately after finishing urinating and walking away from the toilet was omitted as an example of urinary symptom in the PGI - S and PGI - I , since accidental urinary leakage was already included .", "label": "", "metadata": {}, "score": "89.27864"}
{"text": "Postmicturition dribble defined as urine leakage almost immediately after finishing urinating and walking away from the toilet was omitted as an example of urinary symptom in the PGI - S and PGI - I , since accidental urinary leakage was already included .", "label": "", "metadata": {}, "score": "89.27864"}
{"text": "Study conception and design .Schumacher , Sundy , Mellis , Stahl , Yancopoulos , Weinstein , Radin .Acquisition of data .Knapp , Mellis , Soo , King - Davis , Weinstein , Radin .", "label": "", "metadata": {}, "score": "90.28041"}
{"text": "Urate crystals induce an inflammatory response in part by promoting activation of the multiprotein NLRP3 inflammasome in macro- phages , which results in caspase 1 cleavage and activa- tion , and processing and release of IL-1 ?", "label": "", "metadata": {}, "score": "91.06319"}
{"text": "Additionally , patients with impaired renal or hepatic function or an abnormal serum profile were excluded from the study .Patients ' body weight could not exceed 100 kg .", "label": "", "metadata": {}, "score": "91.172195"}
{"text": "He is also a speaker for Roche .RLM is an employee of Genentech .LLT is a consultant of Roche .AK has received research grants and consulting fees from Roche .", "label": "", "metadata": {}, "score": "91.284546"}
{"text": "In der Behandlung der Gichtarthritis wurden zuletzt neue Therapeutika etabliert , aber auch das lange Zeit eingesetzte Kolchizin wurde in seiner Verwendung optimiert .Die Therapie der rheumatoiden Arthritis wurde in den letzten Jahren durch die Einf\u00fchrung der Biologika revolutioniert .", "label": "", "metadata": {}, "score": "91.59631"}
{"text": "Tocilizumab is a humanised , monoclonal , anti - interleukin ( IL ) 6 receptor antibody that binds to both soluble and membrane - bound IL-6 receptor , inhibiting IL-6R signal transduction to inflammatory mediators .", "label": "", "metadata": {}, "score": "91.81893"}
{"text": "Western Ontario and McMaster Universities Osteoarthritis Index . 0.001 1.8 53.8 23.1 12.6 8.7 [ 32 ] 1.8 30.6 34.5 21.8 11.3 ?Data in square brackets are numbers of missing or not applicable observations .", "label": "", "metadata": {}, "score": "92.330475"}
{"text": "Ann Intern Med .[ PMID : 15611487 ] 34 .Vas J , Me \u00b4 ndez C , Perea - Milla E , Vega E , Panadero MD , Leo \u00b4 n JM , et al .", "label": "", "metadata": {}, "score": "92.5361"}
{"text": "Professor Dr H Moutsopoulos , Dr F N Skopouli , Dr G Linardaki , University of Athens School of Medicine , Athens .The Netherlands : Professor Dr F C Breedveld , Dr C F Allaart , Academisch Ziekenhuis Leiden , Leiden ; Professor Dr L B A van de Putte , Professor Dr P L C M van Riel , Dr A A den Broeder , Academisch Ziekenhuis Nijmegen , Nijmegen .", "label": "", "metadata": {}, "score": "93.48106"}
{"text": "Adalimumab is an IgG1 , engineered using phage display technology with amino acid sequences from the human germ line , making it indistinguishable in structure and function from natural human IgG1 .", "label": "", "metadata": {}, "score": "93.99237"}
{"text": "Talk with your doctor and family members or friends about deciding to join a study .To learn more about this study , you or your doctor may contact the study research staff using the Contacts provided below .", "label": "", "metadata": {}, "score": "94.1533"}
{"text": "Dr. Maier : Department of Pain Management , BG - Kliniken Bergmanns- heil , Buerkle de la Camp Platz 1 , D-44789 Bochum , Germany .", "label": "", "metadata": {}, "score": "94.78061"}
{"text": "Current author addresses and author contributions are available at www .annals.org .References 1 .Knutson K , Lewold S , Robertsson O , Lidgren L. The Swedish knee arthro- plasty register .", "label": "", "metadata": {}, "score": "94.87794"}
{"text": "Berlin : Springer ; 2001:171 - 85 .Berman BM , Singh BB , Lao L , Langenberg P , Li H , Hadhazy V , et al .", "label": "", "metadata": {}, "score": "95.34966"}
{"text": "Spearman CE : The proof and measurement of association between two things .Am J Psychol 1904 , 15 : 72 - 101 .View Article .", "label": "", "metadata": {}, "score": "95.3855"}
{"text": "BMJ .Page 10 .Current Author Addresses : Dr. Scharf : Orthopedic Clinic , University Hospital Mannheim , Theodor - Kutzer - Ufer 1 - 3 , D-68167 Mannheim , Germany .", "label": "", "metadata": {}, "score": "95.52612"}
{"text": "Drafting of the article : H.-P. Scharf , U. Mansmann , K. Streitberger , S. Witte , N. Victor .Critical revision of the article for important intellectual content : H.-P. Scharf , U. Mansmann , K. Streitberger , S. Witte , N. Victor .", "label": "", "metadata": {}, "score": "95.58772"}
{"text": "According to the traditional Chinese theory of the Bi syndrome to treat knee pain , the most important local acu- puncture points were included as obligatory points ( 17- 19 ) .", "label": "", "metadata": {}, "score": "95.83867"}
{"text": "[ 6 ] 3.0 ( 1.9 to 3.7 ) [ 14 ] - P ? 0.001 - P ? 0.003 - P ? 0.06 7.0 ( 5.9 to 8.1 ) [ 15 ] 5.9 ( 4.9 to 6.9 ) [ 8]3.5 ( 2.5 to 4.5 ) [", "label": "", "metadata": {}, "score": "95.86027"}
{"text": "2.14 to ? 1.63 ) [ 7 ] ? 1.18 to ? 0.64 ) [ 8 ] ? 1.50 to ? 1.29 to ? 2.49 to ? 1.94 ) [ 8 ] ? 2.29 to ? 1.77 ) [ 5 ] ? 1.47 to ? 0.91 ) [ 10 ] ? 1.35 to ? 1.16 to ? 0.11 to 0.51 ) ? 0.15 to 0.50 ) ?", "label": "", "metadata": {}, "score": "96.177765"}
{"text": "\" [ Show abstract ] [ Hide abstract ] ABSTRACT : Acupuncture , an ancient East Asian therapy , is aimed at rectifying the imbalance within the body caused by disease .", "label": "", "metadata": {}, "score": "96.62981"}
{"text": "[ Show abstract ] [ Hide abstract ] ABSTRACT : Rheumatische Erkrankungen manifestieren sich in jedem Lebensalter .Zwischen dem 40 .und 60 .Lebensjahr finden sich geh\u00e4uft Erstmanifestationen der Gichtarthritis .", "label": "", "metadata": {}, "score": "96.65619"}
{"text": "Switzerland : Professor Dr B Michel , Dr T Langenegger , Dr D Frey , Universit\u00e4tsspital - Rheumaklinik , Zurich ; Professor Dr T Vischer , Dr N Buchs , H\u00f4pital Beau - Sejour , Geneva .", "label": "", "metadata": {}, "score": "96.87207"}
{"text": "One point was in the center of the thigh on the connecting line from the center of the patella to the Context The evidence regarding acupuncture for treating osteoar- thritis of the knee has been inconclusive .", "label": "", "metadata": {}, "score": "97.44148"}
{"text": "Page 11 .Appendix Table 2 . 0.14 to 0.37 ) 0.2 ( ? 0.08 to 0.42 ) 3.0 ( 2.77 to 3.28 ) [ 11 ] 3.3 ( 3.06 to 3.55 ) [ 7 ] 4.3 ( 4.04 to 4.56 ) [ 7 ] ? 1.60 to ? 1.31 to ? 0.67 ) 2.9 ( 2.65 to 3.17 ) [ 8 ] 3.2 ( 2.93 to 3.43 ) [ 5 ] 4.0 ( 3.69 to 4.22 ) [ 9 ] ? 1.38 to ? 1.10 to ? 0.05 to 0.60 ) ? 0.05 to 0.59 ) ? 0.32 to 0.31 ) ? 0.31 to 0.31 ) 3.5 ( 3.19 to 3.76 ) [ 11 ] 3.7 ( 3.43 to 3.97 ) [ 7 ] 4.6 ( 4.35 to 4.93 ) [ 7 ] ? 1.53 to ? 1.30 to ? 0.58 ) 3.3 ( 3.02 to 3.59 ) [ 8 ] 3.6 ( 3.29 to 3.83 ) [ 5 ] 4.5 ( 4.16 to 4.74 ) [ 9 ] ? 1.51 to ? 1.25 to ? 0.14 to 0.58 ) ? 0.11 to 0.60 ) ? 0.38 to 0.11 ) 0.0 ( ? 0.23 to 0.25 ) 3.3 ( 3.06 to 3.58 ) [ 12 ] 3.7 ( 3.43 to 3.92 ) [ 7 ] 4.7 ( 4.39 to 4.92 ) [ 7 ] ? 1.67 to ? 1.31 to ? 0.66 ) 3.2 ( 2.93 to 3.45 ) [ 8 ] 3.6 ( 3.30 to 3.80 ) [ 5 ] 4.4 ( 4.11 to 4.64 ) [ 9 ] ? 1.52 to ? 1.16 to ? 2.47 to ? 1.95 ) [ 11 ] ? 2.22 to ? 1.72 ) [ 7 ] ? 1.11 to ? 0.58 ) [ 8 ] ? 1.71 to ? 1.45 to ? 2.60 to ? 2.05 ) [ 8 ] ?", "label": "", "metadata": {}, "score": "98.011765"}
{"text": "0.90 ) [ 10 ] ? 1.49 to ? 1.27 to ? 0.08 to 0.57 ] ? 0.11 to 0.54 ) ? 2.45 to ? 1.83 ) [ 11 ] ? 2.24 to ? 1.66 ) [ 7 ] ? 1.34 to ? 0.72 ) [ 8 ] ? 1.50 to ? 1.30 to ? 2.61 to ? 2.00 ) [ 8 ] ? 2.38 to ? 1.79 ) [ 5 ] ? 1.54 to ? 0.91 ) [ 10 ] ? 1.48 to ? 1.25 to ? 0.19 to 0.57 ) ? 0.17 to 0.61 ) ?", "label": "", "metadata": {}, "score": "98.990814"}
{"text": "Lilly Research Laboratories , Eli Lilly and Company , Indianapolis , IN 46285 , USA .Journal Information Journal ID ( nlm - ta ): BMC Urol Journal ID ( iso - abbrev ): BMC Urol ISSN : 1471 - 2490 Publisher : BioMed Central .", "label": "", "metadata": {}, "score": "101.79098"}
{"text": "About Fampridine - SR .Fampridine - SR is a sustained - release tablet formulation of the investigational drug fampridine ( 4-aminopyridine , or 4-AP ) .", "label": "", "metadata": {}, "score": "102.169945"}
{"text": "Type : Journal Article ; Research Support , Non - U.S. Gov't ; Validation Studies Date : 2012 - 11 - 07 .Journal Detail : .", "label": "", "metadata": {}, "score": "102.9409"}
{"text": "Date Detail : .Created Date : 2012 - 11 - 22 Completed Date : 2013 - 07 - 10 Revised Date : 2013 - 07 - 11 .", "label": "", "metadata": {}, "score": "104.15475"}
{"text": "I-17 Web - Only Appendix Tables Conversion of figure and tables into slides Annals of Internal Medicine Article 12 \u00a9 2006 American College of Physicians .", "label": "", "metadata": {}, "score": "104.93091"}
{"text": "Multisite .Twenty - six cancer centers in Austria , Belgium , Croatia , France , Poland , and the Netherlands .Study Design : .", "label": "", "metadata": {}, "score": "105.713615"}
{"text": "In MS , the myelin becomes damaged and the axon can not effectively transmit electrical impulses .Specifically , the damaged myelin exposes channels in the membrane of the axon , which allow potassium ions to leak from the axon , dissipating the electrical current .", "label": "", "metadata": {}, "score": "106.36916"}
{"text": "Rilonacept is a recombinant fusion protein consisting of the extra- cellular ligand - binding domains of human IL-1 type I receptor and IL-1 receptor accessory protein , fused to the Fc portion of human IgG1 ( 14 ) .", "label": "", "metadata": {}, "score": "110.3533"}
{"text": "Nlm Unique ID : 100968571 Medline TA : BMC Urol Country : England .Other Details : .Languages : eng Pagination : 30 Citation Subset : IM .", "label": "", "metadata": {}, "score": "110.64873"}
{"text": "All postings are the responsibility of the poster .All logos and trademarks in this site are property of their respective owners .All users must respect our rules for intellectual property rights .", "label": "", "metadata": {}, "score": "110.751144"}
{"text": "J Urol 1998 , 160 ( 4 ) : 1358 - 1367 .PubMed View Article .Pre - publication history .Copyright .\u00a9 Viktrup et al . ; licensee BioMed Central Ltd. 2012 .", "label": "", "metadata": {}, "score": "112.948"}
{"text": "See also : Print Editors ' Notes . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .", "label": "", "metadata": {}, "score": "115.26189"}
{"text": "Acknowledgments .Belgium : Professor Dr M Malaise , Dr O Kaye , Dr B Andr\u00e9 , CHU Li\u00e8ge , Li\u00e8ge ; Professor Dr E M J C Veys , Dr K Vanderkerckhove , University Hospital Ghent , Ghent .", "label": "", "metadata": {}, "score": "115.44683"}
{"text": "Fampridine - SR Mechanism of Action .A nerve cell has one extension , called an axon , which it uses to communicate via electrical signals to other nerve cells .", "label": "", "metadata": {}, "score": "124.74265"}
